

TITLE:

COVID19-related and all-cause mortality among middle-aged and older adults across the first epidemic wave of SARS-COV-2 infection in the region of Tarragona, Spain: results from the COVID19 TARRACO Cohort Study, March-June 2020.

AUTHORS:

Angel Vila-Corcoles^{a,b}, Eva Satue-Gracia^{a,b}, Angel Vila-Rovira^b, Cinta de Diego-Cabanes^a, Maria Jose Forcadell-Peris^a and Olga Ochoa-Gondar^{a,b}.

AFFILIATION:

^aPrimary Care Department Camp de Tarragona. Institut Catala de la Salut, Tarragona, Spain.

^bUniversitary Institute of Primary Care Research IDIAP Jordi Gol. Barcelona, Spain.

CORRESPONDENCE:

Olga Ochoa-Gondar. Unitat de Suport a la Recerca Tarragona-Reus. Institut Catala de la Salut C/ Rambla Nova 124, Tarragona 43001. Email: oochoa.tgn.ics@gencat.cat

SUMMARY

Background: Direct and indirect COVID19-related mortality is uncertain. This study investigated COVID19-related and all-cause deaths among middle-aged and older adults during the first wave of COVID19 epidemic period, assessing mortality risks by pre-existing socio-demographic and medical underlying conditions.

Methods: Population-based cohort study involving 79,083 individuals ≥ 50 years-old in Tarragona (Southern Catalonia, Spain). Baseline cohort characteristics (age/sex, comorbidities and medications/vaccinations history) were established at study start (01/03/2020) and main outcomes were COVID19-related deaths (occurred in patients diagnosed with the disease) and all-cause deaths occurred among cohort members between 01/03/2020-30/06/2020. Mortality risks were assessed by Cox regression analyses.

Results: Cohort members were followed for 1,356,358 persons-weeks, occurring 576 all-cause deaths (124 COVID19-related). All-cause mortality rate was 42.5 deaths per 100,000 persons-week, being 22.8 in healthy/unrelated-COVID19 subjects, 236.4 in COVID19-excluded/PCR-negative subjects, 493.7 in COVID19-compatible/PCR-unperformed subjects and 4009.1 in COVID19-confirmed patients. In multivariable analyses, increasing age, sex male, nursing-home residence, cancer, neurologic, cardiac or liver disease, receiving diuretics, systemic corticosteroids, proton-pump inhibitors and benzodiazepines were associated with increased risk of all-cause mortality; conversely, receiving renin-angiotensin inhibitors and statins were associated with reduced risk. Age/years, sex male and nursing-home residence were strong predictors for COVID19-related mortality, but none comorbidity appeared significantly associated with an increased risk.

Conclusion: Apart from direct COVID19-related deaths (which represented almost 22% of all-cause mortality), theoretically COVID19-excluded patients (PCR-negative) suffered considerable greater all-cause mortality than healthy/unrelated-COVID19 subjects, which could explain, in part, the large excess deaths observed across the COVID19 pandemic.

KEYWORDS: Coronavirus, SARS-COV-2, COVID19, Mortality, Risk.

INTRODUCTION

A year ago, following an outbreak of pneumonia in Wuhan (China), a new coronavirus was detected. Said virus, later named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is the cause of the disease designated by the World Health Organization (WHO) as COVID19 in February 2020.[1] Currently, the pandemic caused by this virus continues to be a threat to public health worldwide.[2]

Available publications have reported different percentages of asymptomatic or mild cases of COVID19 but, even if they account for around 80%,[2,3] due to the high infectivity of the virus, the number of disease's related deaths is very high.[2] The mortality rates reported are very heterogeneous, depending on the countries (with important differences between regions, even within the same country), and also on the availability / policy of conducting diagnostic tests.[2]. For example, in Lombardy (Italy) the case fatality rate ranged between 1.6% and 18.3%,[4] while the Chinese Centre for Disease Control and Prevention, in a cohort of 72,314 cases, estimated a 2.3% case-fatality rate (14.8% for patients ≥ 80 years)[5]. Most articles report in-hospital mortality or case fatality rates (mortality rate among confirmed cases); it must be taken into account that infection fatality rate (which consider all infected individuals) would be lower. On the other hand, many deaths from COVID19 occur in undiagnosed patients. Lastly, we have to keep in mind the "excess mortality" (deaths caused by other conditions, linked to a delay in care, overburden of the health system and socioeconomic determinants of health).[6,7]

In the case of Spain, the latest scientific-technical report of the Ministry of Health (dated November 12) informed a fatality rate of 11% in patients ≥ 50 years (reaching 19% in the group ≥ 70 years compared to 0.45% in aged 50-69 years).[8] However, the estimates that took into account the results of the seroprevalence study (done in May)[9] reported much lower rates: 0.04% in the younger (50-69 years) and 4.1% in those ≥ 70 years, with a global rate for ≥ 50 years of 1.5%.[8] According to the Statistics National Institute (INE), as compared with 2019, almost a 20% increased all-cause death occurred in Spain during 2020 (surely as consequence of COVID19 pandemic).[10]

Most reviews agree that age and gender are well-established risk factors of mortality in COVID19 patients,[11,12] but there is no clear consensus on the specific contribution of pre-existing conditions to the risk of mortality from the disease.[13] Knowing the relative contribution of factors related to the patient (including socio-demographic and medical aspects) to mortality is very important to identify the individuals with greater risk and guarantee a more efficient use of resources.

This study investigated COVID19-related and all-cause mortality among middle-aged and older adults in the region of Tarragona across the first epidemic wave (March-June 2020), assessing the possible association between previous conditions (demographic, comorbidities, chronic medications' use) and risk of death (COVID19-related and/or any cause) among middle-aged and older adults (who support the greatest burden of severe disease).

METHODS

Design, setting and study population

This is part of a large population-based retrospective-prospective cohort study (initiated in March 2020 and called *COVID19 TARRACO Cohort Study*) involving 79,083 individuals 50 years or older in the region of Tarragona (Southern Catalonia, Spain).

The design, setting and study population have been extensively described elsewhere, in prior articles that evaluated the epidemiology of COVID-19 during the first 8-12 weeks of epidemic period in the study area.[14,15]

The 79,083 cohort members were all individuals ≥ 50 years-old affiliated to the 12 Primary Care Centres (PCCs) managed by the *Institut Català de la Salut* in the study area (*Tarragonés*, *Alt Camp* and *Conca de Barberà* counties) and represented approximately 75% of overall inhabitants in this age strata according to census data.[16] This report focuses on cohort members who died (by COVID-19 or any cause) in the study setting between March 1 and June 30, 2020. The study was approved by the Ethical Committee of the Institution (Ethics Committee *IDIAP Jordi Gol*, Barcelona, file 20/065-PCV) and was conducted in accordance with the general principles for observational studies.[17] The study was determined to be exempt for informed consent under the public health surveillance exception.

Data sources

Former CAPAMIS Research Database, an institutional clinical database used for earlier cohort studies in the region,[18] was updated and exploited as the prime data source in this COVID-19 epidemiological report. Summarily, this database collects inputs from the electronic system (e-CAP) of primary care clinical records, that includes administrative and clinical data, coded according to the International Classification of Diseases 10th Revision (ICD-10). It allowed us to identify socio-demographic aspects and previous conditions/comorbidities among cohort members in order to define their baseline profile at study onset (01/03/2020).

Two new electronic alerts, related to COVID-19's laboratory results and ICD-10 codes for COVID-19 suspicion (B34.2, B97.29) were introduced to the e-CAP system at the beginning of the epidemic; later, both information sources were bonded to create the baseline research database utilised in this study.

Vital status was considered according to administrative data periodically updated in the e-CAP system. In addition, complementary data registered during emergency visits and/or hospital-stays, were used to complement vital status data in COVID-19 cases identified across study period. These data were transferred to a standardised form, after retrospective review of electronic records carried out by a research-trained group of family physicians and were afterwards linked with the prime research database containing baseline characteristics of 79,083 cohort members.

Outcome definitions

Primary outcome was death from any cause (COVID19-related or not) occurred among cohort members during the 4-month of study period (01/03/2020-30/06/2020). Laboratory-confirmed COVID-19 case was defined when a cohort member tested positive in SARS-COV-2 using Reverse Transcription-Polymerase Chain Reaction (RT-PCR) or serological tests, according institutional guidelines.[19] COVID19-related death was considered when the patient died from any cause within the first 30-days after the onset of the disease or at any time during hospital-stay. Death by COVID-19 (likely due to COVID-19) or death with COVID-19 (likely due to other concomitant causes) were differentiated according to family physician's criteria after checking hospital and primary care clinical records in each of deceased COVID19 cases.

Covariates

Baseline covariates were age, sex, type of residence (community-dwelling or nursing-home), vaccinations' history, previous comorbidities and chronic medications' use; they were considered according to data registered in the e-CAP system.

Criteria used to define comorbidities and chronic medication use are extensively described in an appendix elsewhere.[15] Unrecorded comorbidities, medications or vaccinations were considered as absent.

In addition, at the end of the study period, according to their COVID-19 relation, cohort members were classified as: COVID19-unrelated/healthy, COVID19-excluded (PCR/serological test performed with negative result), COVID19-compatible (clinical suspicion alone, without any test performed) and COVID19-confirmed (positive PCR or serological test).

Statistical analysis

Descriptive statistics of socio-demographic and clinical variables include frequencies/percentages for categorical variables; and means/ standard deviations (SD) for continuous variables. Chi-squared or Fisher test (categorical variables) and Student's t test (continuous variables) were used for comparison of differences between groups.

Mortality Rates (MRs) for COVID19-related and all-cause deaths were calculated per 100,000 persons-week, considering in the denominator the sum of the persons-time contributed for each cohort member during the study period (17.4 weeks). The confidence intervals (CIs) for the MRs were calculated assuming a Poisson distribution for uncommon events.

Cox regression analyses were used to calculate unadjusted, age&sex-adjusted and multivariable-adjusted hazards ratios (HRs) and estimate the association between baseline conditions and the time to the first outcome (COVID19-related or all-cause death) occurred among cohort members throughout the study period (from 1st March to 30th June 2020). All exposure above mentioned covariates (i.e., age, sex, residence, comorbidities/underlying conditions, chronic medications' use and vaccinations' history) were considered for multivariable Cox models; the method to select a subset of covariates to include in final models was the purposeful selection.[20] Final models include both significant or confounder variables and all covariates judged clinically or epidemiologically relevant. We performed a main analysis including the total study cohort (N=79,083) and two subgroup analyses restricted to community-

dwelling individuals (N=77,669) and nursing-home residents (N=1414), which are shown in supplementary tables. The analyses were performed using IBM SPSS Statistics for Windows, version 24 (IBM Corp., Armonk, N.Y., USA); in all of them, statistical significance was set at $p < 0.05$ (two-tailed).

RESULTS

The study cohort included 79,083 persons (37,626 [47.6%] men and 41,407 [52.4%] women), with a mean age of 65.8 years (SD: 11.3). By age groups, 42,684 (54%) were aged 50-64 years and 10,386 (13.1%) were aged 80 years or older. A total of 77,669 (98.2%) were community-dwelling and 1414 (1.8%) nursing-home residents.

Cohort members were observed for a total of 1,356,358 persons-weeks (1,335,069 for community-dwelling and 21,289 for nursing-home residents). An amount of 4113 (5.2%) of the 79,083 cohort members was tested for SARS-COV-2 infection across study period; 3577 (87%) were negative and 536 (13%) positive (345 in community-dwelling and 191 in nursing-home residents). Two hundred and eighty-three cohort members (280 community-dwelling and 3 nursing-home residents) had a suspected COVID-19 without PCR testing (Table 1).

Across the four-month study period, 576 all-cause deaths were observed (413 in community-dwelling and 163 in nursing-home residents), of which 124 occurred among laboratory-confirmed COVID19 patients and were considered COVID19-related deaths (63 in community-dwelling and 61 in nursing-home residents). Of these 124 deceased patients with laboratory-confirmed COVID19, 112 (90.3%) died by (due to) COVID-19, while 12 (9.7%) died with COVID19 but likely due to other causes according to physician reviewers' criteria after checking clinical records (ten cases in community dwelling and two cases in nursing-home residents).

All-cause mortality rate was 42.5 deaths per 100,000 persons-week (95% CI: 39.2-46.1) considering the total study cohort. By residence, it was 30.9 per 100,000 persons-week (95% CI: 28.0-34.1) in community-dwelling and 765.7 per 100,000 persons-week (95% CI: 653.9-896.6) in nursing-home residents.

COVID19-related mortality rate was 9.1 per 100,000 persons-week considering the total study cohort, being 4.7 per 100,000 persons-week among community-dwelling and 286.5 per 100,000 persons-week among nursing-home residents. Therefore, deaths from COVID19 represented a 21.5% (124/576) of the overall deaths observed in the total study cohort (15.3% [63/413] in community-dwelling vs 37.4% [61/163] in nursing-home residents).

Of the 576 all-cause deaths, 295 occurred among the 74,687 COVID19-unrelated/ healthy subjects (22.8 deaths per 100,000 persons-week), 150 among the 3577 COVID19-excluded/PCR-negative subjects (236.4 deaths per 100,000 persons-week), 7 among the 283 COVID19-suspected/PCR-unperformed (493.7 deaths per 100,000 persons-week) and 124 among the 536 COVID19-confirmed subjects (4009.1 deaths per 100,000 persons-week) (Table 2).

Table 3 shows univariate analyses reporting all-cause deaths (n=576) by age, sex and pre-existing conditions (comorbidities, chronic medications' use and vaccinations' history) in the total study cohort. Table 4 reports it for COVID19-related deaths (n=124). Tables 5 and 6 show Cox regression analyses assessing unadjusted, age&sex-adjusted and multivariable-adjusted risks of suffer all-cause death and COVID19-related death, respectively, in the total study cohort.

Supplementary tables S1-S4 show subgroup analyses restricted to community-dwelling individuals and supplementary tables S5-S8 show subgroup analyses restricted to nursing-home residents.

After multivariable-adjustments assessing risks of all-cause mortality in the total study cohort (see Table 5), increasing age/years (HR: 1.08; 95% CI: 1.07-1.09; p<0.001), male sex (HR: 1.47; 95% CI: 1.24-1.79; p<0.001), nursing-home residence (HR: 1.63; 95% CI: 1.28-2.09; p<0.001), neurological disease (HR: 1.48; 95% CI: 1.18-1.85; p=0.001), cancer (HR: 2.46; 95% CI: 2.03-2.98; p<0.001), cardiac disease (HR: 1.29; 95% CI: 1.06-1.56; p=0.009), liver disease (HR: 1.76; 95% CI: 1.14-2.73; p=0.012), receiving diuretics (HR: 1.55; 95% CI: 1.27-1.88; p<0.001), systemic corticosteroids (HR: 3.49; 95% CI: 2.59-4.70; p<0.001), proton-pump inhibitors (HR: 1.25; 95% CI: 1.03-1.51; p=0.026) and benzodiazepines (HR: 1.34; 95% CI: 1.11-1.61; p=0.003) were associated with a significant increased risk. Conversely, receiving Angiotensin Converting Enzyme inhibitors (ACEIs) (HR: 0.73; 95% CI: 0.60-0.88; p=0.001), Angiotensin II Receptor Blockers (ARBs) (HR: 0.59; 95% CI: 0.46-0.77; p<0.001) and statins (HR: 0.72; 95% CI: 0.59-0.88; p=0.002) were associated with a reduced risk. In subgroup analyses restricted to community-dwelling individuals, the results did not substantially change (see supplementary Table S3). In subgroup analysis restricted to nursing-home residents (see supplementary Table S7), history of tetanus vaccination was associated with a reduced risk (HR: 0.65; 95% CI: 0.44-0.97; p=0.036).

If we consider COVID19-related mortality (see Table 6), many comorbidities (cancer, neurological, renal, respiratory, cardiac disease, diabetes and hypertension) appeared associated with an increased risk in the crude analyses. However, after age&sex-adjustment only neurological, respiratory and cardiac disease were associated with increased risk, and none of them appeared significantly associated with an increased risk after multivariable-adjustment. In this analysis, increasing age/years (HR: 1.08; 95% CI: 1.06-1.10; p<0.001), male sex (HR: 1.82; 95% CI: 1.24-2.70; p=0.003) and nursing-home residence (HR: 12.56; 95% CI: 8.07-19.54; p<0.001) were the strongest predictors for COVID19-related mortality. Considering chronic medications' use, while many medications were associated with an increased risk in crude analyses, none of them altered the risk of COVID19-related death in multivariable analysis (except for ARBs [HR: 0.52; 95% CI: 0.26-1.01; p=0.054] and oral antidiabetic drugs [HR: 2.14; 95% CI: 1.03-4.43; p=0.042], that were marginally associated with reduced and increased risk, respectively).

In subgroup analyses restricted to community-dwelling individuals evaluating risk of COVID19-related mortality, besides age/years and male sex, taking diuretics (HR: 1.89; 95% CI: 1.03-3.46; p=0.041) and systemic corticosteroids (HR: 3.10; 95% CI: 1.27-7.59; p=0.013) emerged associated with increased risk. None other medication, comorbidity and/or vaccination's history

altered the risk of COVID19-related death after multivariable-adjustments in these community-dwelling individuals (see supplementary Table S4).

In subgroup analyses restricted to nursing-home residents, apart from increasing age and male sex, only receiving antineoplastic agents (HR: 3.81; 95% CI: 1.00-14.44; p=0.049) and, surprisingly, influenza vaccination in prior autumn (HR: 2.34; 95% CI: 1.08-5.07; p=0.031) significantly altered the risk of COVID19-related death after multivariable adjustment (see supplementary Table S8).

DISCUSSION

Direct and indirect mortality due to COVID19 is controversial.[4,5,8,11,13,21,22] This study investigated all-cause and COVID19-related deaths among middle-aged and older adults in the region of Tarragona (Southern Catalonia, Spain) across the first wave of COVID19 epidemic period (March-June 2020), assessing mortality risks by demographic characteristics and underlying medical conditions. Of note, the study was conducted in a region with relatively low incidence of COVID19 as compared with other European and Spanish regions.[2,3,8]

As main findings, all-cause mortality rate across study period was 42.5 deaths per 100,000 persons-week, and COVID19-related deaths represented 21.5% of overall deaths. Considering specifically COVID19-related deaths (those occurred among patients with laboratory-confirmed COVID19), 90.3% died by COVID-19 and 9.7% died with COVID19 (i.e., the death may be attributed to other baseline or concomitant cause).

Increasing age, male sex, and nursing-home residence appear as the strongest predictors for both COVID19-related death and all-cause death. Other pre-existing conditions may also alter mortality risk, especially some comorbidities and chronic medications' use, which emerged significantly related with all-cause mortality risk.

Importantly, apart from COVID19-related deaths (occurring among patients with laboratory-confirmed COVID19), theoretically COVID19-excluded patients (i.e., those persons with a negative PCR) suffered ten times greater all-cause mortality than unrelated-COVID19/healthy subjects. This fact suggests that, apart from baseline excess risk in PCR-negative subjects (who were older and had more comorbidities than healthy/COVID19-unrelated subjects), some of the observed excess mortality in PCR-negative subjects could be due to undiagnosed/undetected COVID19 despite PCR performed. In this sense, we note that the reliability of PCR testing depends on the quality of the nasopharyngeal samples collected, timing of collection and sensitivity of tests used,[19] which could explain, in part, the excess all-cause mortality observed in PCR-negative subjects in this study.

Regarding excess mortality, the Statistics National Institute (INE) reported an increase in deceases in 2020 (compared to 2019) of 18.95%; which corresponds in absolute numbers to 70,715 deaths, of which only 43,131 were attributed to COVID19.[10] The considerably larger all-cause mortality in PCR-negative subjects observed in the present study may reflect

COVID19 underdiagnosis and could explain, in part, some excess all-cause deaths observed across the current COVID19 pandemic.

We note the importance of providing adjusted data instead of crude data. Thus, while crude all-cause mortality rate was almost 25-times greater in nursing-home (766 deaths per 100,000 persons-week) than in community-dwelling individuals (31 deaths per 100,000 persons-week), we found that after multivariable adjustments (by age/sex and pre-existing conditions) nursing-home residence only increased approximately 1.6 times the adjusted risk of all-cause mortality (HR: 1.63; 95% CI: 1.28-2.09) as compared with community-dwelling. In this same way, apart from increasing age and sex male, many pre-existing conditions appeared significantly associated with an increased risk of COVID19-related mortality in the crude analysis (and several in the age&sex-adjusted analysis), but none comorbidity emerged significantly associated with an increased risk after multivariable adjustment.

This highlights the importance of maximizing adjusted data assessing event's risk in observational studies. In fact, this could explain distinct/opposite data reported in different studies evaluating relationships between some pre-existing comorbidities/conditions and susceptibility/risk of suffering COVID19 infection or death.[4,5,11,13, 21-26] To illustrate it, besides subgroup analyses, we reported all unadjusted, age&sex-adjusted and multivariable-adjusted results here, which is a major strength in this study.

Considering chronic medication, there is scarce data reporting the possible influence of previous use of these drugs on the risk of COVID19-related mortality. We did not observe any significant association in this sense but, interestingly, receiving statins and renin-angiotensin inhibitors were significantly associated with a lower risk of all-cause mortality in our study cohort.

Major strengths in this study were the large size and representativity of the cohort (that included more than 79,000 people, which represents approximately 75% of overall population over 50 years of age in the study area, and the use of survival analysis methods to accurately estimate both risks of all-cause and COVID19-related mortality by distinct important population subgroups (based in its relation with COVID19): COVID19-confirmed subjects, COVID19-suspected subjects (without PCR performed), COVID19-excluded subjects (negative PCR testing) and COVID19-unrelated/healthy subjects). The large size of the study cohort together with the adjustment of major possible confounding variables (e.g., age, type of residence, pre-existing underlying conditions/comorbidities and chronic medications' use) in the multivariable analyses may provide an acceptable basis to assess mortality risk among the general population ≥ 50 years across the first wave of COVID19 epidemic period in our setting.

Major limitations in this study are related with its retrospective design and scarce availability of PCR tests during the first weeks of study period. Indeed, considering that PCR testing was not routinely performed for all clinically compatible/suspected COVID19 patients across the study period, the laboratory-confirmed COVID19 cases (and, consequently, the number of COVID19-related deaths) were likely underestimated. Then, all-cause mortality (which is not influenced by the frequency of PCR testing) may be a better measure of COVID19 pandemic impact. As another limitation, the study was conducted in a single geographical area and, logically, specific

mortality data may not be directly extrapolated to other geographical regions with distinct epidemic conditions.

The authors recognise these inherent limitations but note that, opposite to many papers reporting only crude COVID19 data, the present study provides age&sex-adjusted and multivariable-adjusted data evaluating both all-cause and COVID19-related mortality risks. Importantly, the estimations may considerably vary depending on type of analyses/adjustments performed; therefore, we underline again the importance of maximizing adjustments. We did subgroup analysis (nursing-home/community-dwelling) and multivariable-adjustments, but, as in all observational studies, a residual confounding due to unmeasured factors (e.g., socio-economical, lifestyle, job- or healthcare-related factors) cannot be excluded.

CONCLUSIONS

In summary, in this large cohort study including 79,083 middle-aged and older adults followed across the first wave of COVID19 epidemic period in the region of Tarragona, we found that deaths from COVID19 represented 21.5% of all-cause mortality occurred across study period (March-June 2020). Increasing age, sex male, nursing-home residence, cancer, neurologic, cardiac or liver disease, receiving diuretics, systemic corticosteroids, proton-pump inhibitors and benzodiazepines were associated with an increased risk of all-cause mortality; conversely, receiving renin-angiotensin inhibitors and statins were associated with a reduced risk. Age/years, sex male and nursing-home residence were strong predictors for COVID19-related mortality, but no comorbidity was independently associated with increased risk.

Interestingly, apart from COVID19-related deaths (approximately 10% of them could be attributed to another baseline or concomitant cause), theoretically COVID19-excluded patients (PCR-negative) suffered considerable greater all-cause mortality than healthy/unrelated-COVID19 subjects. This data suggests COVID19 underdiagnosis and it could explain, in part, the unexpected excess deaths observed during the COVID19 pandemic.

CONTRIBUTORS: AVC designed the study; AVC and ESG assessed outcomes and wrote the manuscript; ESG, CDC and MFP obtained data; ESG and AVR did statistical analyses and edited the manuscript; OOG revised the final version; AVC coordinated the study.

FUNDING: This study is supported by a grant from the Instituto de Salud Carlos III of the Spanish Health Ministry (file COV20/00852; call for the SARS-COV-2/COVID-19 disease, RDL 8/2020, March 17, 2020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

COMPETING INTEREST: All authors, none declared.

REFERENCES

1. World Health Organization (WHO). Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. Available at: <http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020> (Accessed December 9, 2020).
2. European Centre for Disease Prevention and Control. Novel coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK—sixth update—12 March 2020. Stockholm: ECDC; 2020.
3. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. *PLoS Med.* 2020;17(9):e1003346. Published 2020 Sep 22. doi:10.1371/journal.pmed.1003346
4. Odone A., Delmonte D., Scognamiglio T., Signorelli C. COVID-19 deaths in Lombardy, Italy: data in context. *Lancet Public Heal.* 2020;5. doi: 10.1016/S2468-2667(20)30099-2.
5. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med* 2020; 180:934.
6. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020; 584:430.
7. Gold JAW, Rossen LM, Ahmad FB, et al. Race, Ethnicity, and Age Trends in Persons Who Died from COVID-19 - United States, May-August 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69:1517.
8. Gobierno de España. Secretaría General de Sanidad y Consumo. Dirección General de Salud Pública, Calidad e innovación. Centro de Coordinación de Alertas y Emergencias Sanitarias. Información científica-técnica. Enfermedad por coronavirus, COVID-19 Actualización 12 de noviembre, 2020. Available at: <https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/TCoronavirus.pdf>. (Accessed December 5, 2020).
9. Instituto de Salud Carlos III. Estudio ENE-COVID19: informe final. Estudio nacional de sero-epidemiología de la infección por SARS-CoV-2 en España. July 6, 2020. Available at: https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf. (Accessed December 5, 2020).
10. Instituto Nacional de Estadística (INE). Estimación del número de defunciones semanales durante el brote de COVID-19. Available at: https://www.ine.es/experimental/defunciones/experimental_defunciones.htm. (Accessed December 5, 2020).
11. Figliozzi S, Masci PG, Ahmadi N, et al. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. *Eur J Clin Invest.* 2020;50(10):e13362. doi:10.1111/eci.13362.
12. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis* 2020; 20:669.
13. Ejaz H, Alsrhani A, Zafar A, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. *J Infect Public Health.* 2020;13(12):1833-1839. doi:10.1016/j.jiph.2020.07.014.
14. Vila-Córcoles Á, Ochoa-Gondar O, Torrente-Fraga C, et al. Evaluación de la incidencia y perfil de riesgo de Covid-19 según comorbilidad previa en adultos ≥ 50 años del área de Tarragona. *Rev Esp Salud Pública* 2020; 94: e202006065.
15. Vila-Córcoles A, Ochoa-Gondar O, Satué-Gracia EM, et al. Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain. *BMJ Open.* 2020 Dec 10;10(12):e041577.
16. IDESCAT. Statistical Institute of Catalonia. Available at: <https://www.idescat.cat/?lang=en>. (Accessed December 20, 2020]
17. World Medical Association. WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. Available at: <https://www.wma.net/policies-post/wmadeclaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>. (Accessed December 20, 2020).
18. Vila-Corcoles A, Hospital-Guardiola I, Ochoa-Gondar O, et al. Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke. *BMC Public Health.* 2010;10:25.
19. Generalitat de Catalunya. Subdirecció General de Vigilància i Resposta a Emergències de Salut Pública. Procediment d'actuació enfront de casos d'infecció pel nou coronavirus SARSCoV-2. Available at: https://canalsalut.gencat.cat/web/.content/_A-Z/C/coronavirus-2019-ncov/material-divulgatiu/procediment-actuacio-coronavirus.pdf (Accessed December 20, 2020)

20. Hosmer DW, Lemeshow S. Applied Survival Analysis. Regression Modeling of Time to Event Data. New York: John Wiley & Sons, 1999.
21. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *Int J Infect Dis.* 2020; 94: 91-95.
22. Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. *PLoS One.* 2020;15(8):e0238215.
23. Liang WH, Guan WJ, Li CC, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China. *Eur Respir J.* 2020: 2000562.
24. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. *JAMA* 2020; 323:1574-1581.
25. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 395:1054-62.
26. Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. *CritCare.* 2020; 24:179.

TABLES

Table 1. Distribution of study population according to Covid19 related status at the end of study period. Population over 50 years, Tarragona region (Southern Catalonia, Spain), 01/03/2020-30/06/2020.

COVID19 related status	COVID19 Nonrelated (Healthy) N=74687 n (%)	COVID19 Excluded (PCR-) N=3577 n (%)	COVID19 Suspected (Without PCR) N=283 n (%)	COVID19 Confirmed (PCR+) N=536 n (%)	p-value
Characteristic Sociodemographical					
Age: years, sd	65.5 (11.1)	70.0 (12.8)	60.6 (9.4)	74.0 (11.3)	<0.001
Age group: 50-64 yrs	40799 (54.6)	1492 (41.7)	216 (76.3)	177 (33.0)	<0.001
65-79 yrs	24638 (33.0)	1186 (33.2)	52 (18.4)	137 (25.6)	
≥80 yrs	9250 (12.4)	899 (25.1)	15 (5.3)	222 (41.4)	
Sex Men	35575 (47.6)	1701 (47.6)	115 (40.6)	235 (43.8)	0.036
Women	39112 (52.4)	1876 (52.4)	168 (59.4)	301 (56.2)	
Community-dwelling	73870 (98.9)	3174 (88.7)	280 (98.9)	345 (64.4)	<0.001
Nursing-home residence	817 (1.1)	403 (11.3)	3 (1.1)	191 (35.6)	
Comorbidities					
Neurological disease	1935 (2.6)	293 (8.2)	10 (3.5)	79 (14.7)	<0.001
Renal disease	3982 (5.3)	420 (11.7)	9 (3.2)	65 (12.1)	<0.001
Cancer	5995 (8.0)	549 (15.3)	19 (6.7)	67 (12.5)	<0.001
Rheumatic disease	804 (1.1)	57 (1.6)	4 (1.4)	7 (1.3)	0.032
Inflammatory bowel disease	497 (0.7)	27 (0.8)	2 (0.7)	6 (1.1)	0.567
Respiratory disease	6592 (8.8)	567 (15.9)	33 (11.7)	80 (14.9)	<0.001
Cardiac disease	12232 (16.4)	1016 (28.4)	34 (12.0)	153 (28.5)	<0.001
Atrial fibrillation	3317 (4.4)	392 (11.0)	7 (2.5)	70 (13.1)	<0.001
Liver disease	1338 (1.8)	110 (3.1)	6 (2.1)	11 (2.1)	<0.001
Diabetes	12322 (16.5)	838 (23.4)	31 (11.0)	126 (23.5)	<0.001
Hypertension	32604 (43.7)	1937 (54.2)	114 (40.3)	290 (54.1)	<0.001
Hypercholesterolemia	25638 (34.3)	1398 (39.1)	97 (34.3)	181 (33.8)	<0.001
Obesity	20468 (27.4)	1013 (28.3)	62 (21.9)	135 (25.2)	0.068
Smoking	12074 (16.2)	591 (16.5)	44 (15.5)	41 (7.6)	<0.001
Alcoholism	1644 (2.2)	134 (3.7)	7 (2.5)	11 (2.1)	<0.001
Chronic medications use					
Diuretics	7586 (10.2)	731 (20.4)	25 (8.8)	139 (25.9)	<0.001
Beta blockers	8817 (11.8)	632 (17.7)	35 (12.4)	87 (16.2)	<0.001
ACEIs	15374 (20.6)	872 (24.4)	59 (20.8)	114 (21.3)	<0.001
ARBs	8317 (11.1)	471 (13.2)	27 (9.5)	54 (10.1)	0.001
Calcium channel blockers	5990 (8.0)	420 (11.7)	16 (5.7)	64 (11.9)	<0.001
Statins	15063 (20.2)	936 (26.2)	44 (15.5)	91 (17.0)	<0.001
Oral anticoagulants	3461 (4.6)	385 (10.8)	8 (2.8)	58 (10.8)	<0.001
Antiplatelet drugs	8344 (11.2)	676 (18.9)	26 (9.2)	108 (20.1)	<0.001
Insulin	2726 (3.6)	271 (7.6)	2 (0.7)	43 (8.0)	<0.001
Oral antidiabetic drugs	9855 (13.2)	623 (17.4)	22 (7.8)	85 (15.9)	<0.001
Inhaled respiratory drugs	5628 (7.5)	552 (15.4)	36 (12.7)	77 (14.4)	<0.001
Antineoplastic agents	104 (0.1)	12 (0.3)	0 (0.0)	0 (0.0)	0.017
Systemic corticosteroids	1105 (1.5)	130 (3.6)	7 (2.5)	10 (1.9)	<0.001
NSADs	4079 (5.5)	191 (5.3)	30 (10.6)	21 (3.9)	0.001
Chloroquine	154 (0.2)	11 (0.3)	2 (0.7)	1 (0.2)	0.176
Antihistamines	3085 (4.1)	152 (4.2)	12 (4.2)	15 (2.8)	0.469
Proton-Pump Inhibitors	16254 (21.8)	1423 (39.8)	71 (25.1)	183 (34.1)	<0.001
Benzodiazepines	12026 (16.1)	819 (22.9)	75 (26.5)	126 (23.5)	<0.001
Vaccination's history					
Flu vaccine in prior autumn	20838 (27.9)	1449 (40.5)	61 (21.6)	258 (48.1)	<0.001
PPV23	24189 (32.4)	1666 (46.6)	56 (19.8)	272 (50.7)	<0.001
PCV13	1005 (1.3)	108 (3.0)	8 (2.8)	18 (3.4)	<0.001
Tetanus	47761 (63.9)	2507 (70.1)	187 (66.1)	344 (64.2)	<0.001

NOTE: P-values were calculated by Chi-squared or Fisher's test as appropriate.

Table 2. Distribution of all-cause deaths according to COVID19-related status in cohort members. Tarragona, 01/03/2020-30/06/2020.

Mortality Population	No. of persons	Persons-time follow-up (No. of persons-week)	No. of deaths	Mortality Rate MR (95% CI)
ALL PERSONS	79,083	1356358	576	42.5 (39.2-46.1)
Healthy (non-related COVID19)	74,687	1290922	290	22.5 (20.1-25.2)
COVID19-excluded (PCR-)	3577	60825	145	238.4 (201.2-282.3)
COVID19-suspected (non-PCR tested)	283	1518	7	493.7 (198.0-1017.0)
COVID19-confirmed (PCR+)	536	3093	124	4009.1 (3339.6-4810.9)
COMMUNITY-DWELLING	77,669	1335069	413	30.9 (28.0-34.1)
Healthy (non-related COVID19)	73,870	1277550	228	17.8 (15.7-20.2)
COVID19-excluded (PCR-)	3174	54077	117-3	216.4 (180.3-259.7)
COVID19-suspected (non-PCR tested)	280	1503	3-3	199.6 (41.1-582.8)
COVID19-confirmed (PCR+)	345	1938	63	3250.8 (2503.1-4226.0)
NURSING-HOME	1414	21289	163	765.7 (653.9-896.6)
Healthy (non-related COVID19)	817	13371	67	501.1 (393.4-636.4)
COVID19-excluded (PCR-)	403	6747	33-2	489.1 (340.9-679.8)
COVID19-suspected (non-PCR tested)	3	15	2-2	13333.3 (1613.3-48133.2)
COVID19-confirmed (PCR+)	191	1155	61	5281.4 (4066.7-6865.8)

NOTE: MR denotes mortality rate, and it's calculated for 100,000 persons-week. CI denotes confidence interval.

Table 3. Incidence of all-cause mortality according to baseline demographical and clinical characteristics (comorbidities/medications) in the total study cohort (N=79,083). Tarragona region (Southern Catalonia, Spain), 01/03/2020-30/06/2020.

Characteristic	Study population (N=79083) n (%)	All-cause deaths (n=576)		
		Univariate analysis n (%) p-value	Time follow-up (persons-week)	Mortality rate MR* (95% CI)
Sociodemographical				
Age: 50-64 yrs	42684 (54.0)	54 (9.4) <0.001	734123	7.4 (5.5-9.8)
65-79 yrs	26013 (32.9)	149 (25.9)	447474	33.3 (28.1-39.4)
≥80 yrs	10386 (13.1)	373 (64.8)	174761	213.4 (191.8-237.3)
Sex Men	37626 (47.6)	302 (52.4) 0.019	645470	46.8 (41.7-52.5)
Women	41457 (52.4)	274 (47.6)	710888	38.5 (34.0-43.7)
Community-dwelling	77676 (98.2)	413 (71.7) <0.001	1335069	30.9 (28.0-34.1)
Nursing-home residence	1407 (1.8)	163 (28.3)	21289	765.7 (653.9-896.6)
Comorbidities				
Neurological disease	2317 (2.9)	119 (20.7) <0.001	38344	310.3 (258.5-372.4)
Renal disease	4476 (5.7)	134 (23.3) <0.001	75629	177.2 (149.6-209.8)
Cancer	6630 (8.4)	168 (29.2) <0.001	112481	149.4 (127.6-174.9)
Rheumatic disease	872 (1.1)	10 (1.7) 0.144	14897	67.1 (32.2-123.5)
Inflammatory bowel disease	532 (0.7)	8 (1.4) 0.035	9097	87.9 (37.9-173.2)
Respiratory disease	7272 (9.2)	129 (22.4) <0.001	123794	104.2 (86.8-125.0)
Cardiac disease	13435 (17.0)	263 (45.7) <0.001	228716	115.0 (101.4-130.4)
Atrial fibrillation	3786 (4.8)	114 (19.8) <0.001	63962	178.2 (148.4-213.8)
Liver disease	1465 (1.9)	22 (3.8) <0.001	24998	88.0 (55.2-132.9)
Diabetes	13317 (16.8)	183 (31.8) <0.001	227640	80.4 (69.3-93.3)
Hypertension	34945 (44.2)	406 (70.5) <0.001	597890	67.9 (61.5-75.0)
Hypercholesterolemia	27314 (34.5)	228 (39.6) 0.011	468535	48.74 (43.0-55.2)
Obesity	21678 (27.4)	151 (26.2) 0.518	372086	40.6 (34.7-47.5)
Smoking	12750 (16.1)	60 (10.4) <0.001	219518	27.3 (21.0-35.5)
Alcoholism	1796 (2.3)	17 (3.0) 0.271	30774	55.2 (32.2-88.3)
Chronic medications use				
Diuretics	8481 (10.7)	238 (41.3) <0.001	143357	166.0 (146.4-188.2)
Beta blockers	9571 (12.1)	138 (24.0) <0.001	163450	84.4 (71.2-99.9)
ACEIs	16419 (20.8)	142 (24.7) 0.021	281514	50.4 (42.5-59.7)
ARBs	8869 (11.2)	64 (11.1) 0.937	152376	42.0 (32.3-54.6)
Calcium channel blockers	6490 (8.2)	71 (12.3) <0.001	111107	63.9 (50.2-81.2)
Statins	16134 (20.4)	123 (21.4) 0.569	277237	44.4 (37.0-53.3)
Oral anticoagulants	3912 (4.9)	90 (15.6) <0.001	66424	135.5 (109.6-168.0)
Antiplatelet drugs	9154 (11.6)	173 (30.0) <0.001	155957	110.9 (95.6-128.6)
Insulin	3042 (3.8)	60 (10.4) <0.001	51741	116.0 (89.3-150.8)
Oral antidiabetic drugs	10585 (13.4)	123 (21.4) <0.001	181452	67.8 (56.5-81.4)
Inhaled respiratory drugs	6293 (8.0)	125 (21.7) <0.001	106857	117.0 (97.5-140.4)
Antineoplastic agents	1614 (2.0)	16 (2.8) 0.209	27691	57.8 (33.1-93.6)
Systemic corticosteroids	1252 (1.6)	56 (9.7) <0.001	21030	266.3 (205.1-346.2)
NSADs	4321 (5.5)	10 (1.7) <0.001	74152	13.5 (6.5-24.8)
Chloroquine	168 (0.2)	0 (0.0) 0.266	2867	-
Antihistamines	3264 (4.1)	11 (1.9) 0.007	56243	19.6 (9.8-35.1)
Proton-Pump Inhibitors	17931 (22.7)	312 (54.2) <0.001	305566	102.1 (91.1-114.5)
Benzodiazepines	13046 (16.5)	166 (28.8) <0.001	222537	74.6 (63.7-87.4)
Vaccination's history				
Flu vaccine in prior autumn	22606 (28.6)	355 (61.6) <0.001	385668	92.0 (82.7-102.3)
PPV23	26183 (33.1)	395 (68.6) <0.001	447270	88.3 (80.0-97.5)
PCV13	1139 (1.4)	24 (4.2) <0.001	19272	124.5 (79.8-185.5)
Tetanus	50799 (64.2)	415 (72.0) <0.001	871204	47.6 (43.1-52.6)

NOTE: P-values in univariate analysis were calculated by chi-squared, or Fisher's test as appropriate, comparing percentages in the study population vs all-cause deaths cases; MR denotes mortality rates per 100.000 persons-week; CIs denotes confidence intervals for mortality rates and were calculated assuming a Poisson distribution for uncommon events.

Table 4. Incidence of Covid19-related mortality according to baseline demographical and clinical characteristics (comorbidities/medications) in the total study cohort (N=79,083). Tarragona region (Southern Catalonia, Spain), 01/03/2020-30/06/2020.

Characteristic	Study population (N=79083) n (%)	COVID-19 deaths (n=124)		
		Univariate analysis n (%) p-value	Time follow-up (persons-week)	Mortality rate MR* (95% CI)
Sociodemographical				
Age: 50-64 yrs	42684 (54.0)	3 (2.4) <0.001	734123	0.4 (0.1-1.2)
65-79 yrs	26013 (32.9)	35 (28.2)	447474	7.8 (5.4-10.8)
≥80 yrs	10386 (13.1)	86 (69.4)	174761	49.2 (39.8-61.0)
Sex Men	37626 (47.6)	63 (50.8) 0.471	645470	9.8 (7.5-12.7)
Women	41457 (52.4)	61 (49.2)	710888	8.6 (6.6-11.2)
Community-dwelling	77676 (98.2)	63 (50.8) <0.001	1335069	4.7 (3.6-6.1)
Nursing-home residence	1407 (1.8)	61 (49.2)	21289	286.5 (220.6-372.5)
Comorbidities				
Neurological disease	2317 (2.9)	29 (23.4) <0.001	38344	75.6 (50.7-108.9)
Renal disease	4476 (5.7)	23 (18.5) <0.001	75629	30.4 (19.3-45.6)
Cancer	6630 (8.4)	23 (18.5) <0.001	112481	20.4 (12.9-30.6)
Rheumatic disease	872 (1.1)	0 (0.0) 0.239	14897	-
Inflammatory bowel disease	532 (0.7)	2 (1.6) 0.200	9097	22.0 (2.7-79.4)
Respiratory disease	7272 (9.2)	27 (21.8) <0.001	123794	21.8 (14.4-31.8)
Cardiac disease	13435 (17.0)	54 (43.5) <0.001	228716	23.6 (17.5-31.2)
Atrial fibrillation	3786 (4.8)	23 (18.5) <0.001	63962	36.0 (22.8-54.0)
Liver disease	1465 (1.9)	3 (2.4) 0.639	24998	12.0 (2.5-35.0)
Diabetes	13317 (16.8)	41 (33.1) <0.001	227640	18.0 (12.9-24.5)
Hypertension	34945 (44.2)	79 (63.7) <0.001	597890	13.2 (10.5-16.5)
Hypercholesterolemia	27314 (34.5)	48 (38.7) 0.328	468535	10.2 (7.6-13.5)
Obesity	21678 (27.4)	30 (24.2) 0.421	372086	8.1 (5.5-11.6)
Smoking	12750 (16.1)	11 (8.9) 0.028	219518	5.0 (2.5-9.0)
Alcoholism	1796 (2.3)	3 (2.4) 0.912	30774	9.7 (2.0-28.3)
Chronic medications use				
Diuretics	8481 (10.7)	49 (39.5) <0.001	143357	34.2 (25.4-45.1)
Beta blockers	9571 (12.1)	29 (23.4) <0.001	163450	17.7 (11.9-25.5)
ACEIs	16419 (20.8)	32 (25.8) 0.166	281514	11.4 (7.7-16.3)
ARBs	8869 (11.2)	11 (8.9) 0.408	152376	7.2 (3.6-12.9)
Calcium channel blockers	6490 (8.2)	18 (14.5) 0.010	111107	16.2 (9.6-25.6)
Statins	16134 (20.4)	26 (21.0) 0.876	277237	9.4 (6.1-13.8)
Oral anticoagulants	3912 (4.9)	17 (13.7) 0.001	66424	25.6 (14.9-41.0)
Antiplatelet drugs	9154 (11.6)	35 (28.2) <0.001	155957	22.4 (15.6-31.1)
Insulin	3042 (3.8)	12 (9.7) 0.001	51741	23.2 (12.0-40.6)
Oral antidiabetic drugs	10585 (13.4)	33 (26.6) <0.001	181452	18.2 (12.7-25.3)
Inhaled respiratory drugs	6293 (8.0)	28 (22.6) <0.001	106857	26.2 (17.4-38.0)
Antineoplastic agents	1614 (2.0)	4 (3.2) 0.350	27691	14.4 (3.9-36.9)
Systemic corticosteroids	1252 (1.6)	6 (4.8) 0.004	21030	28.5 (10.5-62.1)
NSADs	4321 (5.5)	0 (0.0) 0.007	74152	-
Chloroquine	168 (0.2)	0 (0.0) 0.607	2867	-
Antihistamines	3264 (4.1)	0 (0.0) 0.021	56243	-
Proton-Pump Inhibitors	17931 (22.7)	56 (45.2) <0.001	305566	18.3 (14.1-23.8)
Benzodiazepines	13046 (16.5)	37 (29.8) <0.001	222537	16.6 (11.6-23.1)
Vaccination's history				
Flu vaccine in prior autumn	22606 (28.6)	88 (71.0) <0.001	385668	22.8 (18.4-28.3)
PPV23	26183 (33.1)	86 (69.4) <0.001	447270	19.2(15.5-23.8)
PCV13	1139 (1.4)	4 (3.2) 0.095	19272	20.8 (5.7-53.2)
Tetanus	50799 (64.2)	82 (66.1) 0.660	871204	9.4 (7.5-11.8)

NOTE: P-values in univariate analysis were calculated by chi-squared, or Fisher's test as appropriate, comparing percentages in the study population vs Covid19-related cases; MR denotes mortality rates per 100.000 persons-week; CIs denotes confidence intervals for mortality rates and were calculated assuming a Poisson distribution for uncommon events.

Table 5. Cox regression analyses assessing unadjusted, age & sex-adjusted and multivariable-adjusted risk of all-cause mortality in the total study cohort (N=79,083). Tarragona region (Southern Catalonia, Spain) from 01/03/2020 to 30/06/2020.

Characteristic	All-cause deaths (n=576)		
	Unadjusted HR (95% CI) p-value	Age & sex adjusted HR (95% CI) p-value	Multivariable HR (95% CI) p-value
Sociodemographical			
Age (continuous yrs)	1.12 (1.12-1.13) <0.001	1.13 (1.12-1.14) <0.001	1.08 (1.07-1.09) <0.001
Sex: women	0.82 (0.70-0.97) 0.020	0.58 (0.49-0.68) <0.001	0.68 (0.56-0.81) <0.001
Nursing-home residence	24.37 (20.33-29.22) <0.001	6.34 (5.18-7.76) <0.001	1.63 (1.28-2.09) <0.001
Comorbidities			
Neurological disease	8.90 (7.28-10.89) <0.001	2.55 (2.06-3.15) <0.001	1.48 (1.18-1.85) 0.001
Renal disease	5.13 (4.22-6.22) <0.001	1.42 (1.17-1.74) 0.001	1.18 (0.95-1.46) 0.130
Cancer	4.55 (3.80-5.44) <0.001	2.64 (2.20-3.17) <0.001	2.46 (2.03-2.98) <0.001
Rheumatic disease	1.59 (0.85-2.97) 0.146	1.42 (0.76-2.65) 0.276	0.89 (0.46-1.71) 0.717
Respiratory disease	2.87 (2.36-3.49) <0.001	1.75 (1.43-2.13) <0.001	1.26 (0.96-1.66) 0.098
Cardiac disease	4.14 (3.51-4.88) <0.001	1.69 (1.43-2.00) <0.001	1.29 (1.06-1.56) 0.009
Atrial fibrillation	4.98 (4.06-6.11) <0.001	1.50 (1.22-1.85) <0.001	0.87 (0.63-1.19) 0.384
Liver disease	2.12 (1.38-3.24) 0.001	2.68 (1.75-4.10) <0.001	1.76 (1.14-2.73) 0.012
Diabetes	2.31 (1.94-2.75) <0.001	1.42 (1.19-1.69) <0.001	1.07 (0.80-1.44) 0.652
Hypertension	3.03 (2.53-3.62) <0.001	1.08 (0.90-1.30) 0.399	1.19 (0.95-1.48) 0.125
Obesity	0.94 (0.78-1.13) 0.513	0.92 (0.76-1.11) 0.274	0.89 (0.73-1.08) 0.219
Smoking	0.60 (0.46-0.79) <0.001	1.79 (1.35-2.38) <0.001	1.30 (0.97-1.74) 0.078
Alcoholism	1.31 (0.81-2.12) 0.273	2.14 (1.31-3.49) 0.002	1.42 (0.86-2.36) 0.173
Chronic medications use			
Diuretics	5.95 (5.04-7.02) <0.001	2.22 (1.86-2.64) <0.001	1.55 (1.27-1.88) <0.001
Beta blockers	2.30 (1.90-2.78) <0.001	1.36 (1.12-1.64) 0.002	1.11 (0.90-1.37) 0.351
ACEIs	1.25 (1.03-1.51) 0.021	0.73 (0.60-0.88) 0.001	0.64 (0.52-0.79) <0.001
ARBs	0.99 (0.76-1.28) 0.927	0.59 (0.46-0.77) <0.001	0.53 (0.40-0.71) <0.001
Calcium channel blockers	1.58 (1.23-2.02) <0.001	0.83 (0.65-1.07) 0.151	0.81 (0.62-1.05) 0.114
Statins	1.06 (0.87-1.29) 0.582	0.72 (0.59-0.88) 0.002	0.73 (0.57-0.92) 0.008
Oral anticoagulants	3.59 (2.87-4.50) <0.001	1.27 (1.01-1.59) 0.041	1.10 (0.77-1.57) 0.594
Antiplatelet drugs	3.30 (2.76-3.95) <0.001	1.37 (1.14-1.64) 0.001	1.20 (0.97-1.49) 0.096
Insulin	2.93 (2.24-3.83) <0.001	1.88 (1.44-2.46) <0.001	1.15 (0.84-1.59) 0.376
Oral antidiabetic drugs	1.76 (1.44-2.15) <0.001	1.19 (0.97-1.45) 0.089	1.19 (0.87-1.62) 0.270
Inhaled respiratory drugs	3.24 (2.66-3.95) <0.001	1.77 (1.45-2.16) <0.001	1.08 (0.82-1.44) 0.575
Antineoplastic agents	1.37 (0.83-2.25) 0.213	1.40 (0.85-2.30) 0.187	0.63 (0.37-1.06) 0.082
Systemic corticosteroids	6.81 (5.17-8.98) <0.001	4.02 (3.05-5.30) <0.001	3.49 (2.59-4.70) <0.001
NSADs	0.31 (0.16-0.57) <0.001	0.52 (0.28-0.98) 0.043	0.65 (0.35-1.23) 0.189
Antihistamines	0.45 (0.25-0.82) <0.001	0.52 (0.29-0.95) 0.034	0.58 (0.32-1.05) 0.073
Proton-Pump Inhibitors	4.06 (3.45-4.78) <0.001	1.81 (1.53-2.14) <0.001	1.25 (1.03-1.51) 0.026
Benzodiazepines	2.06 (1.72-2.47) <0.001	1.45 (1.20-1.74) <0.001	1.34 (1.11-1.61) 0.003
Vaccination's history			
Flu vaccine in prior autumn	4.04 (3.42-4.78) <0.001	1.24 (1.04-1.48) 0.017	1.03 (0.84-1.27) 0.761
PPV23	4.43 (3.72-5.29) <0.001	0.90 (0.75-1.09) 0.287	0.92 (0.72-1.18) 0.517
PCV13	3.01 (2.00-4.53) <0.001	1.81 (1.20-2.72) 0.005	1.13 (0.74-1.73) 0.577
Tetanus	1.44 (1.20-1.72) <0.001	0.83 (0.69-0.99) 0.042	0.88 (0.70-1.10) 0.263
Covid19-related status			
Cas_4C: Covid19-nonrelated	Reference (-) <0.001	Reference (-) <0.001	Reference (-) <0.001
Covid19-negative	10.78 (8.86-13.12) <0.001	6.44 (5.28-7.87) <0.001	4.24 (3.43-5.25) <0.001
Covid19-suspected	21.29 (10.01-45.30) <0.001	35.89 (16.86-76.42) <0.001	33.25 (15.53-71.20) <0.001
Covid19-confirmed	181.20 (144.29-227.54) <0.001	74.31 (58.49-94.40) <0.001	45.97 (35.01-60.37) <0.001

NOTE: HRs denotes Hazard ratios, and were calculated for those who had the condition as compared with those who had not the condition. In multivariable analysis the HRs were adjusted for age (continuous years), sex, residence, pre-existing comorbidities/underlying conditions, chronic medications use, vaccination's history and Covid19-related status across study period. CIs denote confidence intervals.

Table 6. Cox regression analyses assessing unadjusted, age & sex-adjusted and multivariable-adjusted risk of Covid19-related mortality in the total study cohort (N=79,083). Tarragona region (Southern Catalonia, Spain) from 01/03/2020 to 30/06/2020.

Characteristic	COVID-19 deaths (n=124)		
	Unadjusted HR (95% CI) p-value	Age & sex adjusted HR (95% CI) p-value	Multivariable HR (95% CI) p-value
Sociodemographical			
Age (continuous yrs)	1.13 (1.12-1.15) <0.001	1.14 (1.12-1.16) <0.001	1.08 (1.06-1.10) <0.001
Sex: women	0.88 (0.62-1.25) 0.472	0.60 (0.42-0.85) 0.004	0.55 (0.37-0.81) 0.003
Nursing-home residence	57.04 (40.11-81.11) <0.001	17.05 (11.28-25.78) <0.001	12.56 (8.07-19.54) <0.001
Comorbidities			
Neurological disease	10.30 (6.79-15.61) <0.001	2.74 (1.77-4.23) <0.001	1.35 (0.86-2.14) 0.198
Renal disease	3.83 (2.44-6.03) <0.001	0.99 (0.62-1.57) 0.952	0.98 (0.60-1.60) 0.943
Cancer	2.51 (1.59-3.94) <0.001	1.43 (0.90-2.25) 0.130	1.39 (0.86-2.23) 0.178
Rheumatic disease	0.05 (0.01-92.92) 0.433	0.00 (-) 0.939	0.00 (-) 0.974
Respiratory disease	2.77 (1.81-4.24) <0.001	1.66 (1.08-2.55) 0.021	1.17 (0.66-2.08) 0.603
Cardiac disease	3.79 (2.66-5.41) <0.001	1.47 (1.02-2.11) 0.039	1.23 (0.81-1.85) 0.333
Atrial fibrillation	4.58 (2.91-7.20) <0.001	1.30 (0.82-2.07) 0.266	1.08 (0.54-2.16) 0.824
Liver disease	1.32 (0.42-4.15) 0.635	1.71 (0.54-5.37) 0.361	1.17 (0.37-3.77) 0.790
Diabetes	2.45 (1.68-3.56) <0.001	1.50 (1.03-2.19) 0.033	0.85 (0.41-1.77) 0.670
Hypertension	2.22 (1.54-3.21) <0.001	0.74 (0.51-1.07) 0.110	0.79 (0.50-1.24) 0.297
Obesity	0.84 (0.56-1.27) 0.420	0.84 (0.56-1.28) 0.418	0.89 (0.57-1.36) 0.580
Smoking	0.51 (0.27-0.94) 0.031	1.66 (0.87-3.18) 0.126	1.20 (0.61-2.34) 0.600
Alcoholism	1.07 (0.34-3.36) 0.911	1.92 (0.60-6.13) 0.272	1.07 (0.33-3.54) 0.910
Chronic medications use			
Diuretics	5.49 (3.83-7.87) <0.001	1.88 (1.29-2.74) 0.001	1.48 (0.97-2.25) 0.068
Beta blockers	2.22 (1.47-3.37) <0.001	1.30 (0.86-1.97) 0.214	1.24 (0.78-1.98) 0.355
ACEIs	1.33 (0.89-1.99) 0.167	0.77 (0.51-1.15) 0.194	0.77 (0.49-1.22) 0.265
ARBs	0.77 (0.42-1.43) 0.408	0.46 (0.25-0.85) 0.013	0.52 (0.26-1.01) 0.054
Calcium channel blockers	1.90 (1.15-3.13) 0.012	0.99 (0.60-1.63) 0.970	1.14 (0.67-1.94) 0.633
Statins	1.04 (0.67-1.59) 0.877	0.73 (0.47-1.12) 0.147	0.91 (0.54-1.52) 0.709
Oral anticoagulants	3.08 (1.84-5.13) <0.001	1.05 (0.63-1.76) 0.854	0.87 (0.40-1.92) 0.734
Antiplatelet drugs	3.02 (2.04-4.46) <0.001	1.21 (0.81-1.80) 0.356	1.08 (0.67-1.74) 0.750
Insulin	2.69 (1.49-4.89) 0.001	1.72 (0.95-3.13) 0.073	1.01 (0.51-2.02) 0.970
Oral antidiabetic drugs	2.35 (1.58-3.50) <0.001	1.61 (1.08-2.40) 0.019	2.14 (1.03-4.43) 0.042
Inhaled respiratory drugs	3.40 (2.23-5.18) <0.001	1.81 (1.19-2.78) 0.006	1.45 (0.82-2.58) 0.207
Antineoplastic agents	1.60 (0.59-4.33) 0.355	1.65 (0.61-4.47) 0.325	1.55 (0.55-4.39) 0.412
Systemic corticosteroids	3.19 (1.41-7.25) 0.006	1.84 (0.81-4.19) 0.144	1.88 (0.80-4.41) 0.145
NSADs	0.05 (0.01-1.42) 0.078	0.00 (-) 0.949	0.00 (-) 0.968
Antihistamines	0.05 (0.01-2.38) 0.126	0.00 (-) 0.926	0.00 (-) 0.952
Proton-Pump Inhibitors	2.82 (1.98-4.12) <0.001	1.18 (0.83-1.69) 0.361	0.93 (0.61-1.41) 0.716
Benzodiazepines	2.16 (1.47-3.17) <0.001	1.48 (1.00-2.19) 0.052	1.40 (0.93-2.08) 0.104
Vaccination's history			
Flu vaccine in prior autumn	6.14 (4.16-9.04) <0.001	1.82 (1.21-2.73) 0.004	1.55 (0.98-2.47) 0.063
PPV23	4.59 (3.13-6.72) <0.001	0.86 (0.58-1.29) 0.468	1.00 (0.59-1.67) 0.990
PCV13	2.30 (0.85-6.23) 0.101	1.37 (0.51-3.71) 0.537	1.15 (0.41-3.21) 0.794
Tetanus	1.09 (0.75-1.58) 0.659	0.62 (0.43-0.90) 0.013	0.68 (0.43-1.08) 0.103

NOTE: HRs denotes Hazard ratios, and were calculated for those who had the condition as compared with those who had not the condition. In multivariable analysis the HRs were adjusted for age (continuous years), sex, residence, pre-existing comorbidities/underlying conditions, chronic medications use and vaccination's history. CIs denote confidence intervals.

SUPPLEMENTARY TABLES

Supplementary Table S1. Incidence of all-cause mortality according to baseline demographical and clinical characteristics (comorbidities/medications) in community-dwelling individuals (N=77,669). Tarragona region (Southern Catalonia, Spain), 01/03/2020-30/06/2020.

Characteristic	Study population (N=77669) n (%)	All-cause deaths (n=413)		
		Univariate analysis n (%) p-value	Time follow-up (persons-week)	Mortality rate MR* (95% CI)
Sociodemographical				
Age: 50-64 yrs	42533 (54.8)	52 (12.6) <0.001	731553	7.1 (5.3-9.4)
65-79 yrs	25712 (33.1)	134 (32.4)	442706	30.3 (25.6-35.9)
≥80 yrs	9424 (12.1)	227 (55.0)	160810	141.2 (124.5-160.1)
Sex Men	37143 (47.8)	237 (57.4) <0.001	638226	37.1 (32.7-42.1)
Women	40526 (52.2)	176 (42.6)	696843	25.3 (21.8-29.3)
Comorbidities				
Neurological disease	1950 (2.5)	61 (14.8) <0.001	33074	184.4 (142.0-239.7)
Renal disease	4240 (5.5)	98 (23.7) <0.001	72114	135.9 (111.2-165.8)
Cancer	6461 (8.3)	141 (34.1) <0.001	109968	128.2 (108.2-151.8)
Rheumatic disease	860 (1.1)	10 (2.4) 0.011	14699	68.0 (32.6-125.1)
Inflammatory bowel disease	520 (0.7)	7 (1.7) 0.010	8927	78.4 (31.4-161.5)
Respiratory disease	7074 (9.1)	104 (25.2) <0.001	120762	86.1 (70.4-105.0)
Cardiac disease	12923 (16.6)	190 (46.0) <0.001	221049	86.0 (74.1-99.8)
Atrial fibrillation	3560 (4.6)	80 (19.4) <0.001	60657	131.9 (105.3-164.9)
Liver disease	1438 (1.9)	21 (5.1) <0.001	24570	85.5 (52.9-130.8)
Diabetes	12925 (16.6)	130 (31.5) <0.001	221837	58.6 (48.8-70.3)
Hypertension	33992 (43.8)	291 (70.5) <0.001	583619	49.9 (44.5-55.9)
Hypercholesterolemia	26765 (34.5)	170 (41.2) 0.004	460087	36.9 (31.5-43.2)
Obesity	21343 (27.5)	122 (29.5) 0.347	366948	33.2 (27.7-39.8)
Smoking	12640 (16.3)	52 (12.6) 0.042	217755	23.9 (17.7-31.5)
Alcoholism	1756 (2.3)	15 (3.6) 0.060	30125	49.8 (27.9-82.2)
Chronic medications use				
Diuretics	8028 (10.3)	161 (39.0) <0.001	136857	117.6 (100.4-137.7)
Beta blockers	9311 (12.0)	99 (24.0) <0.001	159529	62.1 (50.8-75.8)
ACEIs	16030 (20.6)	104 (25.2) 0.022	275658	37.7 (30.8-46.0)
ARBs	8709 (11.2)	52 (12.6) 0.374	149802	34.7 (25.7-45.8)
Calcium channel blockers	6315 (8.1)	56 (13.6) <0.001	108465	51.6 (39.7-67.1)
Statins	15910 (20.5)	107 (25.9) 0.006	273714	39.1 (32.0-47.7)
Oral anticoagulants	3741 (4.8)	66 (16.0) <0.001	63865	103.3 (81.1-131.2)
Antiplatelet drugs	8809 (11.3)	124 (30.0) <0.001	150896	82.2 (68.5-98.6)
Insulin	2904 (3.7)	41 (9.9) <0.001	49699	82.5 (58.9-112.2)
Oral antidiabetic drugs	10352 (13.3)	90 (21.8) <0.001	178039	50.6 (40.9-62.7)
Inhaled respiratory drugs	6095 (7.8)	103 (24.9) <0.001	103830	99.2 (81.1-121.0)
Antineoplastic agents	1581 (2.0)	11 (2.7) 0.365	27209	40.4 (20.2-72.3)
Systemic corticosteroids	1216 (1.6)	52 (12.6) <0.001	20457	254.2 (188.6-335.5)
NSADs	4305 (5.5)	9 (2.2) 0.003	73888	12.2 (5.6-23.2)
Antihistamines	3221 (4.1)	10 (2.4) 0.078	55545	18.0 (8.6-33.1)
Proton-Pump Inhibitors	17315 (22.3)	235 (56.9) <0.001	296238	79.3 (69.9-89.9)
Benzodiazepines	12654 (16.3)	120 (29.1) <0.001	216635	55.4 (46.1-66.5)
Vaccination's history				
Flu vaccine in prior autumn	21569 (27.8)	223 (54.0) <0.001	370309	60.2 (52.3-69.3)
PPV23	25222 (32.5)	282 (68.3) <0.001	432783	65.2 (58.2-73.1)
PCV13	1115 (1.4)	21 (5.1) <0.001	18935	110.9 (68.6-169.7)
Tetanus	49817 (64.1)	318 (77.0) <0.001	856072	37.1 (33.1-41.6)

NOTE: P-values in univariate analysis were calculated by chi-squared, or Fisher's test as appropriate, comparing percentages in the study population vs all-cause deaths cases; MR denotes mortality rates per 100.000 persons-week; CIs denotes confidence intervals for mortality rates and were calculated assuming a Poisson distribution for uncommon events.

Supplementary Table S2. Incidence of Covid19-related mortality according to baseline demographical and clinical characteristics (comorbidities/medications) in community-dwelling individuals (N=77,669). Tarragona region (Southern Catalonia, Spain), 01/03/2020-30/06/2020.

Characteristic	Study population (N=77669) n (%)	COVID-19 deaths (n=63)		
		Univariate analysis n (%) p-value	Time follow-up (persons-week)	Mortality rate MR* (95% CI)
Sociodemographical				
Age: 50-64 yrs	42533 (54.8)	2 (3.2) <0.001	731553	0.3 (0.1-1.1)
65-79 yrs	25712 (33.1)	30 (47.6)	442706	6.8 (4.6-9.7)
≥80 yrs	9424 (12.1)	31 (49.2)	160810	19.3 (13.0-27.6)
Sex Men	37143 (47.8)	35 (55.6) 0.219	638226	5.5 (3.8-7.6)
Women	40526 (52.2)	28 (44.4)	696843	4.0 (2.7-5.8)
Comorbidities				
Neurological disease	1950 (2.5)	8 (12.7) <0.001	33074	24.2 (10.4-47.7)
Renal disease	4240 (5.5)	13 (20.6) <0.001	72114	18.0 (9.6-30.8)
Cancer	6461 (8.3)	13 (20.6) <0.001	109968	11.8 (6.3-20.2)
Rheumatic disease	860 (1.1)	0 (0.0) 0.401	14699	-
Inflammatory bowel disease	520 (0.7)	2 (3.2) 0.015	8927	22.4 (2.7-80.9)
Respiratory disease	7074 (9.1)	20 (31.7) <0.001	120762	16.6 (10.1-25.6)
Cardiac disease	12923 (16.6)	29 (46.0) <0.001	221049	13.1 (8.8-18.9)
Atrial fibrillation	3560 (4.6)	13 (20.6) <0.001	60657	21.4 (11.4-36.6)
Liver disease	1438 (1.9)	3 (4.8) 0.086	24570	12.2 (2.5-35.6)
Diabetes	12925 (16.6)	20 (31.7) 0.001	221837	9.0 (5.5-13.9)
Hypertension	33992 (43.8)	42 (66.7) <0.001	583619	7.2 (5.1-9.8)
Hypercholesterolemia	26765 (34.5)	24 (38.1) 0.544	460087	5.2 (3.3-7.7)
Obesity	21343 (27.5)	19 (30.2) 0.634	366948	5.2 (3.1-8.1)
Smoking	12640 (16.3)	5 (7.9) 0.073	217755	2.3 (0.7-5.4)
Alcoholism	1756 (2.3)	2 (3.2) 0.625	30125	6.6 (0.8-23.8)
Chronic medications use				
Diuretics	8028 (10.3)	27 (42.9) <0.001	136857	19.7 (13.0-28.8)
Beta blockers	9311 (12.0)	18 (28.6) <0.001	159529	11.3 (6.7-17.9)
ACEIs	16030 (20.6)	15 (23.8) 0.534	275658	5.4 (3.0-8.9)
ARBs	8709 (11.2)	9 (14.3) 0.439	149802	6.0 (2.7-11.4)
Calcium channel blockers	6315 (8.1)	10 (15.9) 0.024	108465	9.2 (4.4-16.9)
Statins	15910 (20.5)	17 (27.0) 0.201	273714	6.2 (3.6-9.9)
Oral anticoagulants	3741 (4.8)	13 (20.6) <0.001	63865	20.4 (10.9-34.9)
Antiplatelet drugs	8809 (11.3)	16 (25.4) <0.001	150896	10.6 (6.1-17.2)
Insulin	2904 (3.7)	5 (7.9) 0.079	49699	10.1 (3.3-23.5)
Oral antidiabetic drugs	10352 (13.3)	17 (27.0) 0.001	178039	9.5 (5.5-15.2)
Inhaled respiratory drugs	6095 (7.8)	21 (33.3) <0.001	103830	20.2 (12.5-30.9)
Antineoplastic agents	1581 (2.0)	1 (1.6) 0.801	27209	3.7 (0.1-20.6)
Systemic corticosteroids	1216 (1.6)	6 (9.5) <0.001	20457	29.3 (10.8-63.9)
NSADs	4305 (5.5)	0 (0.0) 0.054	73888	-
Antihistamines	3221 (4.1)	0 (0.0) 0.099	55545	-
Proton-Pump Inhibitors	17315 (22.3)	33 (52.4) <0.001	296238	11.1 (7.7-15.4)
Benzodiazepines	12654 (16.3)	20 (31.7) 0.001	216635	9.2 (5.6-14.2)
Vaccination's history				
Flu vaccine in prior autumn	21569 (27.8)	35 (55.6) <0.001	370309	9.5 (6.6-13.2)
PPV23	25222 (32.5)	45 (71.4) <0.001	432783	10.4 (7.6-13.9)
PCV13	1115 (1.4)	3 (4.8) 0.026	18935	15.8 (3.3-46.1)
Tetanus	49817 (64.1)	46 (73.0) 0.142	856072	5.4 (3.9-7.2)

NOTE: P-values in univariate analysis were calculated by chi-squared, or Fisher's test as appropriate, comparing percentages in the study population vs Covid19-related cases; MR denotes mortality rates per 100.000 persons-week; CIs denotes confidence intervals for mortality rates and were calculated assuming a Poisson distribution for uncommon events.

Supplementary Table S3. Cox regression analyses assessing unadjusted, age & sex-adjusted and multivariable-adjusted risk of all-cause mortality in community-dwelling individuals (N=77,669). Tarragona region (Southern Catalonia, Spain) from 01/03/2020 to 30/06/2020.

Characteristic	All-cause deaths (n=413)		
	Unadjusted HR (95% CI) p-value	Age & sex adjusted HR (95% CI) p-value	Multivariable HR (95% CI) p-value
Sociodemographical			
Age (continuous yrs)	1.11 (1.10-1.12) <0.001	1.11 (1.10-1.12) <0.001	1.09 (1.08-1.10) <0.001
Sex: women	0.68 (0.56-0.83) <0.001	0.52 (0.43-0.63) <0.001	0.63 (0.51-0.78) <0.001
Comorbidities			
Neurological disease	6.81 (5.19-8.94) <0.001	2.25 (1.70-2.98) <0.001	1.67 (1.25-2.23) 0.001
Renal disease	5.44 (4.34-6.83) <0.001	1.66 (1.31-2.10) <0.001	1.25 (0.97-1.61) 0.085
Cancer	5.77 (4.71-7.07) <0.001	3.35 (2.72-4.12) <0.001	2.87 (2.32-3.55) <0.001
Rheumatic disease	2.23 (1.19-4.17) 0.012	2.00 (1.07-3.74) 0.031	1.12 (0.57-2.17) 0.747
Respiratory disease	3.38 (2.71-4.23) <0.001	2.09 (1.67-2.62) <0.001	1.23 (0.87-1.74) 0.246
Cardiac disease	4.29 (3.54-5.21) <0.001	1.89 (1.55-2.32) <0.001	1.35 (1.07-1.70) 0.011
Atrial fibrillation	5.05 (3.95-6.44) <0.001	1.63 (1.27-2.11) <0.001	1.31 (0.87-1.97) 0.202
Liver disease	2.86 (1.84-4.43) <0.001	3.56 (2.30-5.53) <0.001	2.43 (1.55-3.81) <0.001
Diabetes	2.31 (1.87-2.84) <0.001	1.41 (1.15-1.74) 0.001	1.22 (0.84-1.75) 0.296
Hypertension	3.07 (2.49-3.79) <0.001	1.21 (0.97-1.51) 0.087	1.29 (0.99-1.69) 0.063
Obesity	1.11 (0.90-1.37) 0.350	1.05 (0.85-1.29) 0.683	0.98 (0.78-1.22) 0.834
Smoking	0.74 (0.55-0.99) 0.042	1.83 (1.35-2.49) <0.001	1.59 (1.16-2.19) 0.004
Alcoholism	1.63 (0.98-2.73) 0.062	2.31 (1.37-3.90) 0.002	1.66 (0.97-2.86) 0.065
Chronic medications use			
Diuretics	5.59 (4.59-6.81) <0.001	2.36 (1.91-2.91) <0.001	1.54 (1.21-1.95) <0.001
Beta blockers	2.32 (1.85-2.91) <0.001	1.39 (1.10-1.74) 0.005	0.99 (0.77-1.27) 0.947
ACEIs	1.29 (1.04-1.62) 0.023	0.76 (0.61-0.95) 0.015	0.59 (0.46-0.75) <0.001
ARBs	1.14 (0.85-1.52) 0.377	0.67 (0.50-0.90) 0.008	0.47 (0.34-0.65) <0.001
Calcium channel blockers	1.77 (1.34-2.35) <0.001	0.95 (0.71-1.26) 0.698	0.85 (0.63-1.14) 0.262
Statins	1.36 (1.09-1.69) 0.007	0.86 (0.69-1.07) 0.185	0.70 (0.54-0.91) 0.006
Oral anticoagulants	3.79 (2.91-4.93) <0.001	1.37 (1.05-1.80) 0.020	0.87 (0.55-1.37) 0.537
Antiplatelet drugs	3.37 (2.73-4.16) <0.001	1.45 (1.17-1.80) 0.001	1.14 (0.88-1.48) 0.322
Insulin	2.85 (2.07-3.94) <0.001	1.86 (1.35-2.57) <0.001	1.16 (0.79-1.69) 0.450
Oral antidiabetic drugs	1.81 (1.43-2.29) <0.001	1.18 (0.93-1.49) 0.166	0.98 (0.67-1.42) 0.895
Inhaled respiratory drugs	3.94 (3.15-4.92) <0.001	2.22 (1.77-2.78) <0.001	1.31 (0.92-1.86) 0.134
Antineoplastic agents	1.32 (0.72-2.40) 0.370	1.32 (0.72-2.40) 0.369	0.60 (0.32-1.12) 0.106
Systemic corticosteroids	9.24 (6.91-12.35) <0.001	5.59 (4.17-7.48) <0.001	3.60 (2.61-4.96) <0.001
NSADs	0.38 (0.20-0.74) 0.004	0.59 (0.30-1.14) 0.118	0.58 (0.30-1.13) 0.108
Antihistamines	0.57 (0.31-1.07) 0.081	0.64 (0.34-1.19) 0.159	0.52 (0.27-0.97) 0.040
Proton-Pump Inhibitors	4.63 (3.81-5.62) <0.001	2.25 (1.84-2.76) <0.001	1.60 (1.26-2.01) <0.001
Benzodiazepines	2.11 (1.71-2.61) <0.001	1.59 (1.28-1.98) <0.001	1.34 (1.07-1.67) 0.011
Vaccination's history			
Flu vaccine in prior autumn	3.06 (2.52-3.71) <0.001	1.03 (0.84-1.27) 0.779	0.88 (0.70-1.13) 0.317
PPV23	4.49 (3.65-5.52) <0.001	1.05 (0.83-1.32) 0.688	0.90 (0.67-1.21) 0.477
PCV13	3.72 (2.40-5.77) <0.001	2.21 (1.42-3.43) <0.001	1.14 (0.72-1.82) 0.584
Tetanus	1.87 (1.49-2.36) <0.001	1.06 (0.84-1.34) 0.618	0.94 (0.72-1.23) 0.655

NOTE: HRs denotes Hazard ratios, and were calculated for those who had the condition as compared with those who had not the condition. In multivariable analysis the HRs were adjusted for age (continuous years), sex, pre-existing comorbidities/underlying conditions, chronic medications use and vaccination's history. CIs denote confidence intervals.

Supplementary Table S4. Cox regression analyses assessing unadjusted, age & sex-adjusted and multivariable-adjusted risk of Covid19-related mortality in community-dwelling individuals (N=77,669). Tarragona region (Southern Catalonia, Spain) from 01/03/2020 to 30/06/2020.

Characteristic	COVID-19 deaths (n=63)		
	Unadjusted HR (95% CI) p-value	Age & sex adjusted HR (95% CI) p-value	Multivariable HR (95% CI) p-value
Sociodemographical			
Age (continuous yrs)	1.11 (1.09-1.13) <0.001	1.11 (1.09-1.14) <0.001	1.08 (1.05-1.12) <0.001
Sex: women	0.73 (0.45-1.21) 0.221	0.56 (0.34-0.92) 0.023	0.63 (0.36-1.09) 0.099
Comorbidities			
Neurological disease	5.69 (2.71-11.94) <0.001	1.86 (0.87-3.99) 0.111	1.45 (0.66-3.20) 0.354
Renal disease	4.53 (2.46-8.34) <0.001	1.36 (0.72-2.57) 0.343	1.04 (0.53-2.03) 0.914
Cancer	2.88 (1.57-5.31) 0.001	1.65 (0.89-3.07) 0.112	1.43 (0.76-2.68) 0.271
Rheumatic disease	0.05 (0.00-1914.01) 0.576	0.00 (-) 0.955	0.00 (-) 0.977
Respiratory disease	4.67 (2.75-7.93) <0.001	2.94 (1.72-5.04) <0.001	1.46 (0.63-3.39) 0.379
Cardiac disease	4.29 (2.61-7.04) <0.001	1.90 (1.14-3.19) 0.014	1.41 (0.78-2.56) 0.255
Atrial fibrillation	5.45 (2.96-10.03) <0.001	1.80 (0.95-3.38) 0.071	0.78 (0.25-2.45) 0.673
Liver disease	2.66 (0.84-8.49) 0.098	3.31 (1.04-10.59) 0.043	2.34 (0.71-7.69) 0.161
Diabetes	2.33 (1.37-3.97) 0.002	1.44 (0.84-2.45) 0.181	0.78 (0.25-2.43) 0.664
Hypertension	2.57 (1.52-4.45) <0.001	1.00 (0.58-1.73) 0.997	0.97 (0.50-1.91) 0.936
Obesity	1.14 (0.67-1.95) 0.635	1.07 (0.62-1.84) 0.808	0.93 (0.52-1.64) 0.796
Smoking	0.44 (0.18-1.10) 0.080	1.06 (0.41-2.72) 0.913	0.89 (0.34-2.35) 0.807
Alcoholism	1.42 (0.35-5.80) 0.626	2.05 (0.49-8.56) 0.325	1.68 (0.39-7.31) 0.488
Chronic medications use			
Diuretics	6.54 (3.97-10.77) <0.001	2.80 (1.65-4.78) <0.001	1.89 (1.03-3.46) 0.041
Beta blockers	2.94 (1.70-5.08) <0.001	1.76 (1.02-3.05) 0.043	1.35 (0.73-2.49) 0.341
ACEIs	1.20 (0.67-2.15) 0.535	0.71 (0.40-1.27) 0.246	0.59 (0.30-1.14) 0.114
ARBs	1.32 (0.65-2.67) 0.441	0.78 (0.39-1.58) 0.492	0.53 (0.24-1.17) 0.114
Calcium channel blockers	2.13 (1.08-4.19) 0.028	1.14 (0.58-2.26) 0.699	1.12 (0.55-2.29) 0.753
Statins	1.44 (0.82-2.50) 0.203	0.92 (0.53-1.60) 0.766	0.74 (0.38-1.42) 0.364
Oral anticoagulants	5.17 (2.81-9.51) <0.001	1.93 (1.03-3.60) 0.040	1.38 (0.42-4.46) 0.595
Antiplatelet drugs	2.67 (1.51-4.70) 0.001	1.15 (0.64-2.05) 0.646	0.90 (0.45-1.81) 0.776
Insulin	2.23 (0.89-5.56) 0.086	1.46 (0.59-3.64) 0.418	0.92 (0.33-2.59) 0.879
Oral antidiabetic drugs	2.40 (1.38-4.19) 0.002	1.58 (0.90-2.76) 0.109	2.00 (0.64-6.21) 0.233
Inhaled respiratory drugs	5.91 (3.50-9.98) <0.001	3.41 (2.00-5.82) <0.001	2.03 (0.87-4.73) 0.102
Antineoplastic agents	0.78 (0.11-5.60) 0.801	0.77 (0.11-5.57) 0.798	0.58 (0.08-4.37) 0.592
Systemic corticosteroids	6.69 (2.89-15.52) <0.001	4.05 (1.74-9.42) 0.001	3.10 (1.27-7.59) 0.013
NSADs	0.046 (0.00-5.48) 0.206	0.00 (-) 0.961	0.00 (-) 0.969
Antihistamines	0.047 (0.00-11.44) 0.275	0.00 (-) 0.964	0.00 (-) 0.968
Proton-Pump Inhibitors	3.85 (2.35-6.31) <0.001	1.85 (1.11-3.08) 0.019	1.29 (0.71-2.32) 0.404
Benzodiazepines	2.40 (1.41-4.07) 0.001	1.79 (1.04-3.08) 0.037	1.60 (0.92-2.79) 0.098
Vaccination's history			
Flu vaccine in prior autumn	3.26 (1.98-5.35) <0.001	1.12 (0.66-1.89) 0.686	0.90 (0.49-1.64) 0.721
PPV23	5.21 (3.01-8.99) <0.001	1.28 (0.69-2.36) 0.435	1.37 (0.62-3.04) 0.443
PCV13	3.46 (1.09-11.03) 0.036	2.07 (0.65-6.61) 0.221	1.11 (0.33-3.76) 0.862
Tetanus	1.51 (0.87-2.64) 0.144	0.86 (0.49-1.51) 0.595	0.63 (0.32-1.25) 0.186

NOTE: HRs denotes Hazard ratios, and were calculated for those who had the condition as compared with those who had not the condition. In multivariable analysis the HRs were adjusted for age (continuous years), sex, pre-existing comorbidities/underlying conditions, chronic medications use and vaccination's history. CIs denote confidence intervals.

Supplementary Table S5. Incidence of all-cause mortality according to baseline demographical and clinical characteristics (comorbidities/medications) in nursing-home residents (N=1,414). Tarragona region (Southern Catalonia, Spain), 01/03/2020-30/06/2020.

Characteristic	Study population (N=1414) n (%)	All-cause deaths (n=163)		
		Univariate analysis n (%) p value	Time follow-up (persons-week)	Mortality rate MR* (95% CI)
Sociodemographical				
Age: 50-64 yrs	151 (10.7)	2 (1.2) <0.001	2570	77.8 (9.4-280.9)
65-79 yrs	301 (21.3)	15 (9.2)	4768	314.6 (176.2-519.1)
≥80 yrs	962 (68.0)	146 (89.6)	13951	1046.5 (883.1-1239.1)
Sex: Men	483 (34.2)	65 (39.9) 0.102	7245	897.2 (704.3-1139.4)
Women	931 (65.8)	98 (60.1)	14045	697.8 (570.8-851.3)
Comorbidities				
Neurological disease	367 (26.0)	58 (35.6) 0.003	5270	1100.6 (847.5-1430.8)
Renal disease	236 (16.7)	36 (22.1) 0.050	3515	1024.2 (713.9-1423.6)
Cancer	169 (12.0)	27 (16.6) 0.054	2514	1074.0 (707.8-1568.0)
Rheumatic disease	12 (0.8)	0 (0.0) 0.209	199	-
Inflammatory bowel disease	12 (0.8)	1 (0.6) 0.728	170	588.2 (14.9-3276.3)
Respiratory disease	198 (14.0)	25 (15.3) 0.602	3032	824.5 (533.5-1220.3)
Cardiac disease	512 (36.2)	73 (44.8) 0.015	7666	952.3 (747.6-1209.4)
Atrial fibrillation	226 (16.0)	34 (20.9) 0.071	3305	1028.7 (717.0-1429.9)
Liver disease	27 (1.9)	1 (0.6) 0.199	428	233.6 (5.9-1301.2)
Diabetes	392 (27.7)	53 (32.5) 0.146	5803	913.3 (677.7-1205.6)
Hypertension	953 (67.4)	115 (70.6) 0.361	14270	805.9 (671.3-967.1)
Hypercholesterolemia	549 (38.8)	58 (35.6) 0.366	8449	686.5 (528.6-892.5)
Obesity	335 (23.7)	29 (17.8) 0.060	5138	564.4 (378.1-812.7)
Smoking	110 (7.8)	8 (4.9) 0.146	1763	453.8 (195.6-894.0)
Alcoholism	40 (2.8)	2 (1.2) 0.190	649	308.2 (37.3-1112.6)
Chronic medications use				
Diuretics	453 (32.0)	77 (47.2) <0.001	6501	1184.4 (945.2-1480.5)
Beta blockers	260 (18.4)	39 (23.9) 0.052	3921	994.6 (710.1-1352.7)
ACEIs	389 (27.5)	38 (23.3) 0.202	5856	648.9 (452.3-902.0)
ARBs	160 (11.3)	12 (7.4) 0.090	2574	466.2 (241.0-815.9)
Calcium channel blockers	175 (12.4)	15 (9.2) 0.191	2642	567.8 (318.0-936.9)
Statins	224 (15.8)	16 (9.8) 0.025	3523	454.2 (259.8-735.8)
Oral anticoagulants	171 (12.1)	24 (14.7) 0.273	2559	937.9 (601.2-1397.5)
Antiplatelet drugs	345 (24.4)	49 (30.1) 0.074	5061	968.2 (718.4-1278.0)
Insulin	138 (9.8)	19 (11.7) 0.386	2042	930.5 (560.2-1451.6)
Oral antidiabetic drugs	233 (16.5)	33 (20.2) 0.168	3413	966.9 (673.9-1344.0)
Inhaled respiratory drugs	198 (14.0)	22 (13.5) 0.843	3027	726.8 (455.7-1097.5)
Antineoplastic agents	33 (2.3)	5 (3.1) 0.509	482	1037.3 (336.1-2416.9)
Systemic corticosteroids	36 (2.5)	4 (2.5) 0.937	573	698.1 (189.9-1787.1)
NSADs	16 (1.1)	1 (0.6) 0.506	264	378.8 (9.6-2109.9)
Antihistamines	43 (3.0)	1 (0.6) 0.055	698	143.3 (3.6-798.2)
Proton-Pump Inhibitors	616 (43.6)	77 (47.2) 0.314	9327	825.6 (658.8-1032.0)
Benzodiazepines	392 (27.7)	46 (28.2) 0.880	5902	779.4 (568.2-1044.4)
Vaccination's history				
Flu vaccine in prior autumn	1037 (73.3)	132 (81.0) 0.019	15359	859.4 (725.3-1017.5)
PPV23	961 (68.0)	113 (69.3) 0.692	14487	780.0 (649.7-936.0)
PCV13	24 (1.7)	3 (1.8) 0.880	337	890.2 (183.4-2599.4)
Tetanus	982 (69.4)	97 (59.5) 0.003	15132	641.0 (524.3-782.0)

NOTE: P-values in univariate analysis were calculated by chi-squared, or Fisher's test as appropriate, comparing percentages in the study population vs all-cause deaths cases; MR denotes mortality rates per 100.000 persons-week; CIs denotes confidence intervals for mortality rates and were calculated assuming a Poisson distribution for uncommon events.

Supplementary Table S6. Incidence of Covid19-related mortality according to baseline demographical and clinical characteristics (comorbidities/medications) in nursing-home residents (N=1,414). Tarragona region (Southern Catalonia, Spain), 01/03/2020-30/06/2020.

Characteristic	Study population (N=1414) n (%)	COVID-19 deaths (n=61)		
		Univariate analysis n (%) p value	Time follow-up (persons-week)	Mortality rate MR* (95% CI)
Sociodemographical				
Age: 50-64 yrs	151 (10.7)	1 (1.6) 0.001	2570	38.9 (1.0-216.7)
65-79 yrs	301 (21.3)	5 (8.2)	4768	104.9 (34.0-244.4)
≥80 yrs	962 (68.0)	55 (90.2)	13951	394.2 (303.5-512.5)
Sex: Men	483 (34.2)	28 (45.9) 0.048	7245	386.5 (257.0-560.4)
Women	931 (65.8)	33 (54.1)	14045	235.0 (163.8-326.7)
Comorbidities				
Neurological disease	367 (26.0)	21 (34.4) 0.123	5270	398.5 (246.7-609.7)
Renal disease	236 (16.7)	10 (16.4) 0.949	3515	284.5 (136.6-523.5)
Cancer	169 (12.0)	10 (16.4) 0.274	2514	397.8 (190.9-732.0)
Rheumatic disease	12 (0.8)	0 (0.0) 0.460	199	-
Inflammatory bowel disease	12 (0.8)	0 (0.0) 0.460	170	-
Respiratory disease	198 (14.0)	7 (11.5) 0.561	3032	230.9 (92.6-475.7)
Cardiac disease	512 (36.2)	25 (41.0) 0.428	7666	326.1 (211.0-482.6)
Atrial fibrillation	226 (16.0)	10 (16.4) 0.929	3305	302.6 (145.2-556.8)
Liver disease	27 (1.9)	0 (0.0) 0.265	428	-
Diabetes	392 (27.7)	21 (34.4) 0.232	5803	361.9 (224.0-553.7)
Hypertension	953 (67.4)	37 (60.7) 0.251	14270	259.3 (180.7-360.4)
Hypercholesterolemia	549 (38.8)	24 (39.3) 0.932	8449	284.1 (182.1-423.3)
Obesity	335 (23.7)	11 (18.0) 0.288	5138	214.1 (106.8-383.2)
Smoking	110 (7.8)	6 (9.8) 0.540	1763	340.3 (124.9-741.9)
Alcoholism	40 (2.8)	1 (1.6) 0.567	649	154.1 (3.9-858.3)
Chronic medications use				
Diuretics	453 (32.0)	22 (36.1) 0.491	6501	338.4 (212.2-511.0)
Beta blockers	260 (18.4)	11 (18.0) 0.942	3921	280.5 (140.0-502.1)
ACEIs	389 (27.5)	17 (27.9) 0.949	5856	290.3 (169.2-464.5)
ARBs	160 (11.3)	2 (3.3) 0.043	2574	77.7 (9.4-280.5)
Calcium channel blockers	175 (12.4)	8 (13.1) 0.858	2642	302.8 (130.5-596.5)
Statins	224 (15.8)	9 (14.8) 0.812	3523	255.5 (117.0-485.5)
Oral anticoagulants	171 (12.1)	4 (6.6) 0.175	2559	156.3 (42.5-400.1)
Antiplatelet drugs	345 (24.4)	19 (31.1) 0.210	5061	375.4 (226.0-585.6)
Insulin	138 (9.8)	7 (11.5) 0.644	2042	342.8 (137.5-706.2)
Oral antidiabetic drugs	233 (16.5)	16 (26.2) 0.036	3413	468.8 (268.2-759.5)
Inhaled respiratory drugs	198 (14.0)	7 (11.5) 0.561	3027	231.3 (92.8-476.5)
Antineoplastic agents	33 (2.3)	3 (4.9) 0.172	482	622.4 (128.2-1817.4)
Systemic corticosteroids	36 (2.5)	0 (0.0) 0.197	573	-
NSADs	16 (1.1)	0 (0.0) 0.393	264	-
Antihistamines	43 (3.0)	0 (0.0) 0.157	698	-
Proton-Pump Inhibitors	616 (43.6)	23 (37.7) 0.345	9327	246.6 (156.3-369.9)
Benzodiazepines	392 (27.7)	17 (27.9) 0.979	5902	288.0 (167.9-460.8)
Vaccination's history				
Flu vaccine in prior autumn	1037 (73.3)	53 (86.9) 0.014	15359	345.1 (256.1-455.5)
PPV23	961 (68.0)	41 (67.2) 0.898	14487	283.0 (202.1-384.9)
PCV13	24 (1.7)	1 (1.6) 0.971	337	296.7 (7.5-1652.6)
Tetanus	982 (69.4)	36 (59.0) 0.071	15132	237.9 (165.8-330.7)

NOTE: P-values in univariate analysis were calculated by chi-squared, or Fisher's test as appropriate, comparing percentages in the study population vs Covid19-related cases; MR denotes mortality rates per 100.000 persons-week; CIs denotes confidence intervals for mortality rates and were calculated assuming a Poisson distribution for uncommon events.

Supplementary Table S7. Cox regression analyses assessing unadjusted, age & sex-adjusted and multivariable-adjusted risk of all-cause mortality in nursing-home residents (N=1,414). Tarragona region (Southern Catalonia, Spain) from 01/03/2020 to 30/06/2020.

Characteristic	All-cause deaths (n=163)		
	Unadjusted HR (95% CI) p-value	Age & sex adjusted HR (95% CI) p-value	Multivariable HR (95% CI) p-value
Sociodemographical			
Age (continuous yrs)	1.06 (1.04-1.08) <0.001	1.07 (1.05-1.09) <0.001	1.05 (1.03-1.08) <0.001
Sex: women	0.77 (0.57-1.06) 0.110	0.56 (0.40-0.77) <0.001	0.55 (0.39-0.78) 0.001
Comorbidities			
Neurological disease	1.64 (1.19-2.26) 0.002	1.39 (1.01-1.93) 0.047	1.33 (0.95-1.87) 0.095
Renal disease	1.45 (1.00-2.09) 0.051	1.10 (0.76-1.60) 0.622	1.19 (0.80-1.77) 0.389
Cancer	1.49 (0.98-2.24) 0.061	1.33 (0.88-2.03) 0.176	1.38 (0.89-2.16) 0.151
Rheumatic disease	0.05 (0.01-66.40) 0.413	0.00 (-) 0.956	NA (-) 0.951
Respiratory disease	1.10 (0.72-1.68) 0.670	0.98 (0.64-1.51) 0.937	0.95 (0.56-1.60) 0.845
Cardiac disease	1.45 (1.06-1.97) 0.019	1.22 (0.90-1.66) 0.208	1.09 (0.77-1.54) 0.638
Atrial fibrillation	1.44 (0.98-2.09) 0.061	1.11 (0.76-1.63) 0.582	0.88 (0.52-1.52) 0.654
Liver disease	0.31 (0.04-2.20) 0.240	0.34 (0.05-2.41) 0.278	0.24 (0.03-1.76) 0.161
Diabetes	1.28 (0.92-1.78) 0.140	1.28 (0.92-1.78) 0.140	1.12 (0.66-1.90) 0.683
Hypertension	1.17 (0.84-1.64) 0.358	0.94 (0.67-1.32) 0.703	0.99 (0.67-1.47) 0.976
Obesity	0.68 (0.46-1.02) 0.063	0.80 (0.54-1.20) 0.285	0.79 (0.52-1.21) 0.276
Smoking	0.58 (0.29-1.18) 0.135	1.00 (0.48-2.11) 0.998	0.96 (0.44-2.10) 0.926
Alcoholism	0.40 (0.10-1.62) 0.199	0.54 (0.13-2.19) 0.385	0.43 (0.10-1.83) 0.254
Chronic medications use			
Diuretics	2.01 (1.48-2.73) <0.001	1.63 (1.19-2.22) 0.002	1.68 (1.19) 2.38) 0.003
Beta blockers	1.41 (0.98-2.02) 0.061	1.34 (0.93-1.92) 0.112	1.23 (0.82-1.85) 0.315
ACEIs	0.80 (0.56-1.15) 0.223	0.78 (0.54-1.12) 0.177	0.72 (0.48-1.07) 0.099
ARBs	0.59 (0.33-1.06) 0.075	0.63 (0.35-1.14) 0.124	0.58 (0.31-1.09) 0.091
Calcium channel blockers	0.71 (0.42-1.21) 0.210	0.71 (0.42-1.20) 0.198	0.75 (0.43-1.31) 0.310
Statins	0.56 (0.33-0.93) 0.026	0.76 (0.45-1.28) 0.299	0.67 (0.38-1.19) 0.175
Oral anticoagulants	1.27 (0.82-1.96) 0.284	1.12 (0.72-1.73) 0.616	1.13 (0.60-2.13) 0.713
Antiplatelet drugs	1.37 (0.98-1.92) 0.065	1.22 (0.87-1.71) 0.245	1.33 (0.88-2.02) 0.173
Insulin	1.24 (0.77-2.00) 0.380	1.29 (0.80-2.09) 0.294	0.78 (0.54-1.16) 0.936
Oral antidiabetic drugs	1.32 (0.90-1.93) 0.154	1.43 (0.97-2.10) 0.072	1.52 (0.86-2.67) 0.146
Inhaled respiratory drugs	0.95 (0.60-1.49) 0.813	0.85 (0.54-1.34) 0.484	0.81 (0.47-1.39) 0.438
Antineoplastic agents	1.34 (0.55-3.27) 0.515	1.54 (0.63-3.77) 0.339	1.65 (0.62-4.39) 0.318
Systemic corticosteroids	0.91 (0.34-2.46) 0.856	0.89 (0.33-2.40) 0.814	0.97 (0.35-2.69) 0.948
NSADs	0.51 (0.07-3.67) 0.506	1.21 (0.17-8.73) 0.849	1.42 (0.19-10.42) 0.731
Antihistamines	0.19 (0.03-1.33) 0.093	0.25 (0.03-1.76) 0.162	0.26 (0.04-1.84) 0.176
Proton-Pump Inhibitors	1.15 (0.85-1.57) 0.370	1.01 (0.74-1.37) 0.954	0.86 (0.60-1.25) 0.435
Benzodiazepines	1.02 (0.73-1.44) 0.900	1.08 (0.77-1.53) 0.647	1.07 (0.75-1.54) 0.705
Vaccination's history			
Flu vaccine in prior autumn	1.63 (1.10-2.41) 0.014	1.34 (0.91-1.99) 0.141	1.30 (0.86-1.95) 0.216
PPV23	1.06 (0.76-1.48) 0.732	0.79 (0.56-1.10) 0.157	0.90 (0.59-1.36) 0.616
PCV13	1.13 (0.36-3.55) 0.832	0.96 (0.31-3.03) 0.949	0.82 (0.25-2.68) 0.743
Tetanus	0.61 (0.45-0.83) 0.002	0.68 (0.49-0.93) 0.016	0.65 (0.44-0.97) 0.036

NOTE: HRs denotes Hazard ratios, and were calculated for those who had the condition as compared with those who had not the condition. In multivariable analysis the HRs were adjusted for age (continuous years), sex, pre-existing comorbidities/underlying conditions, chronic medications use and vaccination's history. CIs denote confidence intervals.

Supplementary Table S8. Cox regression analyses assessing unadjusted, age & sex-adjusted and multivariable-adjusted risk of Covid19-related mortality in nursing-home residents (N=1,414). Tarragona region (Southern Catalonia, Spain) from 01/03/2020 to 30/06/2020.

Characteristic	COVID-19 deaths (n=61)		
	Unadjusted HR (95% CI) p-value	Age & sex adjusted HR (95% CI) p-value	Multivariable HR (95% CI) p-value
Sociodemographical			
Age (continuous yrs)	1.05 (1.02-1.08) 0.001	1.06 (1.03-1.09) <0.001	1.06 (1.03-1.10) <0.001
Sex: women	0.60 (0.36-1.00) 0.049	0.45 (0.27-0.76) 0.003	0.46 (0.26-0.83) 0.009
Comorbidities			
Neurological disease	1.53 (0.90-2.60) 0.114	1.37 (0.80-2.35) 0.248	1.19 (0.68-2.08) 0.545
Renal disease	1.01 (0.51-1.99) 0.978	0.76 (0.39-1.51) 0.437	0.87 (0.42-1.80) 0.714
Cancer	1.47 (0.75-2.90) 0.265	1.27 (0.64-2.51) 0.499	1.17 (0.56-2.46) 0.677
Rheumatic disease	0.05 (0.01-6912.09) 0.618	0.00 (-) 0.973	0.00 (-) 0.987
Respiratory disease	0.79 (0.36-1.74) 0.556	0.68 (0.31-1.50) 0.342	0.67 (0.26-1.71) 0.397
Cardiac disease	1.25 (0.75-2.07) 0.400	1.06 (0.64-1.78) 0.814	1.18 (0.66-2.11) 0.578
Atrial fibrillation	1.07 (0.54-2.11) 0.847	0.83 (0.42-1.64) 0.585	1.25 (0.52-2.96) 0.620
Liver disease	0.05 (0.00-169.03) 0.467	0.00 (-) 0.962	0.00 (-) 0.984
Diabetes	1.39 (0.82-2.36) 0.222	1.35 (0.80-2.30) 0.264	0.97 (0.38-2.47) 0.950
Hypertension	0.75 (0.45-1.25) 0.272	0.63 (0.37-1.05) 0.077	0.62 (0.33-1.15) 0.126
Obesity	0.70 (0.36-1.34) 0.277	0.81 (0.42-1.55) 0.521	0.94 (0.47-1.88) 0.861
Smoking	1.25 (0.54-2.89) 0.609	1.86 (0.75-4.62) 0.183	2.09 (0.79-5.49) 0.136
Alcoholism	0.54 (0.08-3.92) 0.546	0.60 (0.08-4.45) 0.619	0.40 (0.05-3.07) 0.376
Chronic medications use			
Diuretics	1.25 (0.74-2.11) 0.397	1.05 (0.62-1.78) 0.855	1.21 (0.67-2.18) 0.527
Beta blockers	1.00 (0.52-1.92) 0.993	0.96 (0.50-1.84) 0.895	1.14 (0.56-2.35) 0.718
ACEIs	1.01 (0.58-1.77) 0.974	1.00 (0.57-1.74) 0.987	0.95 (0.50-1.81) 0.887
ARBs	0.25 (0.06-1.04) 0.056	0.28 (0.07-1.13) 0.073	0.27 (0.06-1.19) 0.084
Calcium channel blockers	1.05 (0.50-2.22) 0.890	1.05 (0.50-2.20) 0.902	1.22 (0.54-2.73) 0.633
Statins	0.90 (0.44-1.82) 0.761	1.13 (0.55-2.36) 0.736	1.13 (0.49-2.61) 0.769
Oral anticoagulants	0.52 (0.19-1.42) 0.202	0.44 (0.16-1.22) 0.117	0.32 (0.09-1.14) 0.079
Antiplatelet drugs	1.84 (1.04-3.26) 0.036	1.25 (0.73-2.16) 0.418	1.21 (0.61-2.38) 0.592
Insulin	1.21 (0.55-2.67) 0.631	1.22 (0.55-2.68) 0.628	0.77 (0.30-1.96) 0.584
Oral antidiabetic drugs	1.44 (0.84-2.47) 0.190	1.89 (1.06-3.38) 0.030	2.69 (1.02-7.07) 0.045
Inhaled respiratory drugs	0.79 (0.36-1.74) 0.558	0.69 (0.31-1.52) 0.357	0.85 (0.34-2.11) 0.729
Antineoplastic agents	2.16 (0.68-6.90) 0.193	2.41 (0.76-7.71) 0.137	3.81 (1.00-14.44) 0.049
Systemic corticosteroids	0.05 (0.00-48.30) 0.389	0.00 (-) 0.969	0.00 (-) 0.980
NSADs	0.050 (0.00-1882.72) 0.575	0.00 (-) 0.972	0.00 (-) 0.989
Antihistamines	0.05 (0.00-27.63) 0.348	0.00 (-) 0.967	0.00 (-) 0.977
Proton-Pump Inhibitors	0.78 (0.46-1.31) 0.345	0.68 (0.40-1.14) 0.145	0.71 (0.38-1.32) 0.278
Benzodiazepines	1.00 (0.57-1.75) 0.997	1.10 (0.62-1.94) 0.744	0.88 (0.49-1.60) 0.677
Vaccination's history			
Flu vaccine in prior autumn	2.52 (1.20-5.30) 0.015	2.16 (1.02-4.56) 0.043	2.34 (1.08-5.07) 0.031
PPV23	0.96 (0.56-1.64) 0.878	0.73 (0.42-1.25) 0.245	0.74 (0.38-1.47) 0.390
PCV13	0.99 (0.14-7.11) 0.988	0.81 (0.11-5.84) 0.832	1.07 (0.14-8.27) 0.952
Tetanus	0.61 (0.36-1.01) 0.055	0.64 (0.38-1.07) 0.089	0.66 (0.34-1.27) 0.210

NOTE: HRs denotes Hazard ratios, and were calculated for those who had the condition as compared with those who had not the condition. In multivariable analysis the HRs were adjusted for age (continuous years), sex, pre-existing comorbidities/underlying conditions, chronic medications use and vaccination's history. CIs denote confidence intervals.